

The Endocrine Society's
CLINICAL | GUIDELINES

Evaluation and Management
of Adult Hypoglycemic Disorders:
An Endocrine Society Clinical Practice Guideline



THE JOURNAL OF
CLINICAL
ENDOCRINOLOGY
& METABOLISM

Authors: Philip E. Cryer, Lloyd Axelrod, Ashley B. Grossman, Simon R. Heller, Victor M. Montori, Elizabeth R. Seaquist, and F. John Service

Co-sponsoring Associations: American Diabetes Association, European Association for the Study of Diabetes, and European Society of Endocrinology

Affiliations: Washington University School of Medicine (P.E.C.), St. Louis, Missouri; Massachusetts General Hospital and Harvard Medical School (L.A.), Boston, Massachusetts; Barts and the London School of Medicine, Queen Mary University of London (A.B.G.), London, United Kingdom; University of Sheffield (S.R.H.), Sheffield, United Kingdom; University of Minnesota (E.R.S.), Minneapolis, Minnesota; and Mayo Clinic (V.M.M., F.J.S.), Rochester, Minnesota

Disclaimer Statement: Clinical Practice Guidelines are developed to be of assistance to endocrinologists by providing guidance and recommendations for particular areas of practice. The Guidelines should not be considered inclusive of all proper approaches or methods, or exclusive of others. The Guidelines cannot guarantee any specific outcome, nor do they establish a standard of care. The Guidelines are not intended to dictate the treatment of a particular patient. Treatment decisions must be made based on the independent judgment of health care providers and each patient's individual circumstances.

The Endocrine Society makes no warranty, express or implied, regarding the Guidelines and specifically excludes any warranties of merchantability and fitness for a particular use or purpose. The Society shall not be liable for direct, indirect, special, incidental, or consequential damages related to the use of the information contained herein.

Evidence-based reviews for this guideline were prepared under contract with The Endocrine Society.

First published in the *Journal of Clinical Endocrinology & Metabolism*, March 2009, 94(3): 709-728

© The Endocrine Society, 2009



THE JOURNAL OF
CLINICAL
ENDOCRINOLOGY
& METABOLISM

The Endocrine Society's
CLINICAL | GUIDELINES

Evaluation and Management
of Adult Hypoglycemic Disorders:
An Endocrine Society Clinical Practice Guideline



THE
ENDOCRINE
SOCIETY®

THE JOURNAL OF
CLINICAL
ENDOCRINOLOGY
& METABOLISM

Table of Contents

Summary of Recommendations.....	4
Method of Development of Evidence-Based Recommendations.....	5
Workup for a Hypoglycemic Disorder.....	6
Evaluation and Management of Hypoglycemia in Persons Without Diabetes Mellitus.....	7
Evaluation and Management of Hypoglycemia in Persons With Diabetes Mellitus.....	15
References.....	26
Order Form.....	35
Reprint Information, Questions & Correspondences.....	Inside Back Cover

Abstract

Objective: The aim is to provide guidelines for the evaluation and management of adults with hypoglycemic disorders, including those with diabetes mellitus.

Participants: The Task Force was composed of a chair, selected by the Clinical Guidelines Subcommittee (CGS) of The Endocrine Society, five additional experts, one methodologist, and a medical writer. The Task Force received no corporate funding or remuneration.

Evidence: Using the recommendations of the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) system, the quality of evidence is graded very low (⊕○○○), low (⊕⊕○○), moderate (⊕⊕⊕○), or high (⊕⊕⊕⊕).

Consensus Process: Consensus was guided by systematic reviews of evidence and discussions during one group meeting, several conference calls, and e-mail communications. The drafts prepared by the task force with the help of a medical writer were reviewed successively by The Endocrine Society's CGS, Clinical Affairs Core Committee (CACC), American Diabetes Association, European Association for the Study of Diabetes, the European Society of Endocrinology, and the Society's Council. The version approved by the CGS and CACC was placed on The Endocrine Society's Web site for comments by members. At each stage of review, the Task Force received written comments and incorporated needed changes.

Conclusions: We recommend evaluation and management of hypoglycemia only in patients in whom Whipple's triad—symptoms, signs, or both consistent with hypoglycemia, a low plasma glucose concentration, and resolution of those symptoms or signs after the plasma glucose concentration is raised—is documented. In patients with hypoglycemia without diabetes mellitus, we recommend the following strategy. First, pursue clinical clues to potential hypoglycemic etiologies—

drugs, critical illnesses, hormone deficiencies, nonislet cell tumors. In the absence of these causes, the differential diagnosis narrows to accidental, surreptitious, or even malicious hypoglycemia or endogenous hyperinsulinism. In patients suspected of having endogenous hyperinsulinism, measure plasma glucose, insulin, C-peptide, proinsulin, β -hydroxybutyrate, and circulating oral hypoglycemic agents during an episode of hypoglycemia and measure insulin antibodies. Insulin or insulin secretagogue treatment of diabetes mellitus is the most common cause of hypoglycemia. We recommend the practice of hypoglycemia risk factor reduction—addressing the issue of hypoglycemia, applying the principles of intensive glycemic therapy, and considering both the conventional risk factors and those indicative of compromised defenses against falling plasma glucose concentrations—in persons with diabetes.

(J Clin Endocrinol Metab 94: 709–728, 2009)

Abbreviations: CSII, Continuous sc insulin infusion; HAAF, hypoglycemia-associated autonomic failure; HbA_{1c}, hemoglobin A_{1c}; MDI, multiple daily insulin injection; MEN-1, multiple endocrine neoplasia, type 1; MRI, magnetic resonance imaging; NIPHS, noninsulinoma pancreatogenous hypoglycemia syndrome; T1DM, type 1 diabetes mellitus; T2DM, type 2 diabetes mellitus.

SUMMARY OF RECOMMENDATIONS

1.0. WORKUP FOR A HYPOGLYCEMIC DISORDER

1.1. We recommend evaluation and management of hypoglycemia only in patients in whom Whipple's triad—symptoms, signs, or both consistent with hypoglycemia, a low plasma glucose concentration, and resolution of those symptoms or signs after the plasma glucose concentration is raised—is documented (1 | ⊕⊕⊕⊕).

2.0. EVALUATION AND MANAGEMENT OF HYPOGLYCEMIA IN PERSONS WITHOUT DIABETES MELLITUS

2.1. Compared with a much less thorough workup, we recommend the following strategy in patients with hypoglycemia without diabetes mellitus (1 | ⊕⊕⊕⊕):

- Review the history, physical findings, and all available laboratory data seeking clues to specific disorders—drugs, critical illnesses, hormone deficiencies, nonislet cell tumors.
- When the cause of the hypoglycemic disorder is not evident, *i.e.* in a seemingly well individual, measure plasma glucose, insulin, C-peptide, proinsulin, and β -hydroxybutyrate concentrations and screen for oral hypoglycemic agents, during an episode of spontaneous hypoglycemia, and observe the plasma glucose response to iv injection of 1.0 mg glucagon. These steps will distinguish hypoglycemia caused by endogenous (or exogenous) insulin from that caused by other mechanisms. Also, measure insulin antibodies.
- When a spontaneous hypoglycemic episode cannot be observed, formally recreate the circumstances in which symptomatic hypoglycemia is likely to occur, *i.e.* during a fast of up to 72 h or after a mixed meal. The findings of symptoms, signs, or both with plasma concentrations of glucose less than 55 mg/dl (3.0 mmol/liter), insulin of at least 3.0 μ U/ml (18 pmol/liter), C-peptide of at

least 0.6 ng/ml (0.2 nmol/liter), and proinsulin of at least 5.0 pmol/liter document endogenous hyperinsulinism; β -hydroxybutyrate levels of 2.7 mmol/liter or less and an increase in plasma glucose of at least 25 mg/dl (1.4 mmol/liter) after iv glucagon indicate mediation of the hypoglycemia by insulin (or by an IGF).

- In a patient with documented fasting or postprandial endogenous hyperinsulinemic hypoglycemia, negative screening for oral hypoglycemic agents, and no circulating insulin antibodies, conduct procedures for localizing an insulinoma. These may include computed tomography or magnetic resonance imaging (MRI), transabdominal and endoscopic ultrasonography, and, if necessary, selective pancreatic arterial calcium injections with measurements of hepatic venous insulin levels.
- Tailor treatment to the specific hypoglycemic disorder, taking into account the burden of hypoglycemia on patient well-being and patient preferences.

3.0. EVALUATION AND MANAGEMENT OF HYPOGLYCEMIA IN PERSONS WITH DIABETES MELLITUS

3.1. We suggest that persons with diabetes become concerned about the possibility of developing hypoglycemia when the self-monitored blood glucose concentration is falling rapidly or is no greater than 70 mg/dl (3.9 mmol/liter) (2 | ⊕○○○).

3.2. Given the established long-term microvascular benefits of glycemic control, we recommend that the therapeutic glycemic goal be the lowest mean glycemia [*e.g.* hemoglobin A_{1c} (HbA_{1c})] that can be accomplished safely in a given patient at a given point in the progression of that individual patient's diabetes (1 | ⊕⊕⊕⊕).

3.3. We recommend that the prevention of hypoglycemia in diabetes involve addressing the issue in each patient contact and, if hypoglycemia is a problem, making adjustments in the regimen based on review and application of the principles of intensive glycemic therapy—diabetes self-

management (supported by education and empowerment), frequent self-monitoring of blood glucose, flexible and appropriate insulin or insulin secretagogue regimens, individualized glycemic goals, and ongoing professional guidance and support—and consideration of each of the known risk factors for hypoglycemia (1 | ⊕⊕⊕⊕).

3.4. We recommend that both the conventional risk factors and those indicative of compromised defenses against hypoglycemia be considered in a patient with recurrent treatment-induced hypoglycemia (1 | ⊕⊕⊕⊕). The conventional risk factors are excessive or ill-timed dosing of, or wrong type of, insulin or insulin secretagogue and conditions under which exogenous glucose delivery or endogenous glucose production is decreased, glucose utilization is increased, sensitivity to insulin is increased, or insulin clearance is decreased. Compromised defenses against hypoglycemia are indicated by the degree of endogenous insulin deficiency, a history of severe hypoglycemia, hypoglycemia unawareness, or both as well as recent antecedent hypoglycemia, prior exercise or sleep, and lower glycemic goals *per se*.

3.5. With a history of hypoglycemia unawareness (*i.e.* recurrent hypoglycemia without symptoms), we recommend a 2- to 3-wk period of scrupulous avoidance of hypoglycemia, with the anticipation that awareness of hypoglycemia will return in many patients (1 | ⊕⊕⊕⊕).

3.6. Unless the cause is easily remediable, we recommend that an episode of severe hypoglycemia should lead to a fundamental review of the treatment regimen and the glycemic goals (1 | ⊕⊕⊕⊕).

3.7. We recommend that urgent treatment of hypoglycemia should be accomplished by ingestion of carbohydrates if that is feasible, or by parenteral glucagon or glucose if it is not feasible (1 | ⊕⊕⊕⊕).

METHOD OF DEVELOPMENT OF EVIDENCE-BASED RECOMMENDATIONS

The Task Force followed the approach recommended by the GRADE system (1) with guidance from the methodologist (V.M.M.). A detailed description of this grading scheme has been published (2). In brief, strong recommendations use the phrase “we recommend” and the number 1, and weak recommendations use the phrase “we suggest” and the number 2. The Task Force has confidence that patients who receive care according to the recommendations will derive, on average, more good than harm. Suggestions require more careful consideration of the patient’s circumstances, values, and preferences. Cross-filled circles (⊕) indicate the quality of the evidence: ⊕○○○ denotes very low quality evidence; ⊕⊕○○, low quality; ⊕⊕⊕○, moderate quality; and ⊕⊕⊕⊕, high quality. The quality of the evidence indicates the panel’s confidence that the estimates of risks and benefits associated with the recommended course of action compared with an alternative course of action are correct and unlikely to change importantly with new research.

Linked to each recommendation is a description of the *Evidence*, the *Values* that panelists considered in making the recommendation (when making these explicit was necessary), and *Remarks*, a section in which panelists offer technical suggestions for testing conditions. The latter come from the unsystematic observations of the panelists and should, therefore, be considered suggestions.

1.0. WORKUP FOR A HYPOGLYCEMIC DISORDER

1.0. Recommendation

1.1. We recommend evaluation and management of hypoglycemia only in patients in whom Whipple's triad—symptoms, signs, or both consistent with hypoglycemia, a low plasma glucose concentration, and resolution of those symptoms or signs after the plasma glucose concentration is raised—is documented (1 | ⊕⊕⊕⊕).

1.1. Evidence

Clinical hypoglycemia is a plasma (or serum) glucose concentration low enough to cause symptoms and/or signs, including impairment of brain function. The clinical manifestations of hypoglycemia are nonspecific, it is not possible to state a single plasma glucose concentration that categorically defines hypoglycemia, and a low measured plasma glucose concentration can be artifactual. Therefore, hypoglycemia is confirmed by documentation of Whipple's triad (3): symptoms, signs, or both consistent with hypoglycemia, a low plasma glucose concentration, and resolution of those symptoms or signs after the plasma glucose concentration is raised. In the absence of Whipple's triad, the patient may be exposed to unnecessary evaluation, costs, and potential harms, without expectation of benefit. This very large potentially beneficial effect of documenting Whipple's triad upgrades the evidence (based on consistent clinical observations), thus supporting a rating of high quality. (A rare exception would be a patient who is physically unable to communicate symptoms.)

Symptoms of hypoglycemia are categorized as neuroglycopenic (the result of brain glucose deprivation *per se*) and neurogenic or autonomic (largely the result of the perception of physiological changes caused by the sympathoadrenal discharge triggered by hypoglycemia) (4). Awareness of hypoglycemia is mainly the result of the perception of neurogenic symptoms (4), which are largely

sympathetic neural, rather than adrenomedullary, in origin (5). Some neurogenic symptoms, such as palpitations, tremor, and arousal/anxiety, are adrenergic whereas others, such as sweating, hunger, and paresthesias, are cholinergic (4). Neuroglycopenic symptoms (4) range from behavioral changes, fatigue, and confusion to seizure and loss of consciousness, *i.e.* functional brain failure (6). Seemingly complete recovery after the glucose level is raised is the rule, although on rare occasions neurological recovery is delayed. Profound, prolonged hypoglycemia can cause brain death (6). Signs of hypoglycemia, such as diaphoresis and pallor, are often subtle, although neuroglycopenic manifestations are often observable.

In healthy individuals, symptoms of hypoglycemia develop at a mean plasma glucose concentration of approximately 55 mg/dl (3.0 mmol/liter) (7). However, the glycemic thresholds for this and other responses to hypoglycemia shift to lower plasma glucose concentrations in patients with recurrent hypoglycemia (7–10). Furthermore, whereas arteriovenous plasma glucose concentration differences are clinically negligible in the postabsorptive state, antecubital venous plasma glucose concentrations are as much as one third lower than arterial glucose concentrations (which are relevant to maintaining brain glucose metabolism) when insulin secretion is increased substantially, *e.g.* after a glucose load, causing glucose extraction across the forearm (11). Finally, because of the provision of alternative circulating fuels to the brain (specifically ketones), lower plasma glucose concentrations occur in healthy individuals, particularly in women and children, without symptoms or signs during extended fasting (7). For all of these reasons, it is not possible to state a single plasma glucose concentration that categorically defines hypoglycemia.

Plasma glucose concentrations used to document Whipple's triad, in the absence of insulin or insulin secretagogue treatment of diabetes, must be measured with a reliable laboratory method, not with self-monitoring of blood glucose. Although a distinctly low, reliably measured plasma glucose concentration obtained in the absence of recognized symptoms or signs should not be ignored, that finding raises the possibility of “pseudohypoglycemia”—an artifact of

continued glucose metabolism by the formed elements of the blood after the sample is drawn. That may occur when the blood sample is collected in a tube that does not contain an inhibitor of glycolysis and separation of the plasma (or serum) from the formed elements is delayed, particularly in the setting of erythrocytosis, leukocytosis, or thrombocytosis (12).

Documentation of Whipple's triad establishes that a hypoglycemic disorder exists. Its etiology may be apparent (*e.g.* in a patient with insulin-treated diabetes) or a diagnostic challenge (*e.g.* in a seemingly well individual with an insulinoma). On the other hand, in a person who does not have diabetes mellitus an unequivocally normal plasma glucose concentration [*e.g.* >70 mg/dl (3.9 mmol/liter) (7)] during a symptomatic episode indicates that those symptoms are not the result of hypoglycemia.

1.1. Values

Hypoglycemia is rare in persons who do not have drug-treated diabetes mellitus (12–15). Furthermore, not requiring Whipple's triad to initiate a workup will very likely expose patients who do not have a specific pathology causing hypoglycemia to unnecessary evaluations, costs, and potential harms without expectation of benefit. Therefore, we believe it is important to document Whipple's triad before concluding that a hypoglycemic disorder exists. On the other hand, hypoglycemia is common in persons with insulin- or insulin secretagogue-treated diabetes mellitus (12, 16). Confirmation of Whipple's triad, *e.g.* with self-monitoring of blood glucose, during an episode of suspected hypoglycemia is advisable in such a patient. However, if that is not practical, it is reasonable to assume the episode is caused by hypoglycemia for therapeutic purposes because the probability of that assumption is high and the potential negative impact of an untreated episode is considerable.

2.0. EVALUATION AND MANAGEMENT OF HYPOGLYCEMIA IN PERSONS WITHOUT DIABETES MELLITUS

Background

Because of the effectiveness of the normal defenses against falling plasma glucose concentrations (7), hypoglycemia is an uncommon clinical event (12–15) except in persons who use drugs that lower plasma glucose levels, particularly insulin or an insulin secretagogue, to treat diabetes mellitus (12, 16). Hypoglycemia is a fact of life for most persons with type 1 diabetes and many with type 2 diabetes. Although persons with diabetes are not spared the risk for the same hypoglycemic disorders as those without diabetes, the vast majority of their hypoglycemic episodes are the result of treatment of their diabetes. Furthermore, the pathophysiology of hypoglycemia in diabetes is distinct, and the diagnostic and management approaches are different from those in individuals without diabetes (12, 16). Therefore, we address hypoglycemia in persons without diabetes and in those with diabetes separately.

Physiology and pathophysiology

Glucose is an obligate metabolic fuel for the brain under physiological conditions (6, 7). Because the brain cannot synthesize glucose, use physiological circulating concentrations of alternative fuels effectively, or store more than a few minutes' supply as glycogen, maintenance of brain function, and ultimately survival, requires a virtually continuous supply of glucose from the circulation. That, in turn, requires maintenance of the plasma glucose level within the physiological range because blood-to-brain glucose transport is a direct function of the arterial plasma glucose concentration. Redundant glucose counterregulatory mechanisms normally effectively prevent or rapidly correct hypoglycemia (7). The critical physiological defenses include: 1) a decrease in insulin secretion as glucose levels

decline within the physiological range; 2) an increase in glucagon secretion; or, in its absence, 3) an increase in epinephrine secretion, both occurring as glucose levels decline just below the physiological range. Increased cortisol and GH secretion are involved in defense against prolonged hypoglycemia. If these defenses fail to abort the episode, plasma glucose levels will continue to fall. Symptoms, which prompt the behavioral defense of food ingestion, normally develop at a mean plasma glucose concentration of approximately 55 mg/dl (3.0 mmol/liter). At that and lower glucose levels, insulin secretion is suppressed virtually completely (7, 17); plasma insulin levels are below 3 μ U/ml (18 pmol/liter), C-peptide levels are below 0.6 ng/ml (0.2 nmol/liter), and proinsulin levels are below 5.0 pmol/liter (14).

Because external losses are normally negligible, hypoglycemia develops when the sum of glucose utilization from the circulation (largely by the brain but also by obligatory glycolytic tissues, such as the renal medullae and erythrocytes, and insulin-sensitive tissues, such as muscle) exceeds the sum of glucose delivery into the circulation (from ingested carbohydrates and hepatic and renal glucose production) (12–15). Because of the capacity to increase endogenous glucose production substantially, hypoglycemia is typically the result of absolutely low rates of glucose production or rates of glucose production that are low relative to high rates of glucose utilization.

Recommendation

2.1. Compared with a much less thorough workup, we recommend the following strategy in patients with hypoglycemia without diabetes mellitus (1 | ⊕⊕⊕○):

- Review the history, physical findings, and all available laboratory data seeking clues to specific disorders—drugs, critical illnesses, hormone deficiencies, nonislet cell tumors.
- When the cause of the hypoglycemic disorder is not evident, *i.e.* in a seemingly well individual, measure plasma glucose, insulin, C-peptide, proinsulin, and β -hydroxybutyrate concentrations and screen for oral hypoglycemic agents, during an episode of spontaneous hypoglycemia, and observe

the plasma glucose response to iv injection of 1.0 mg glucagon. These steps will distinguish hypoglycemia caused by endogenous (or exogenous) insulin from that caused by other mechanisms. Also, measure insulin antibodies.

- When a spontaneous hypoglycemic episode cannot be observed, formally recreate the circumstances in which symptomatic hypoglycemia is likely to occur, *i.e.* during a fast of up to 72 h or after a mixed meal. The findings of symptoms, signs, or both with plasma concentrations of glucose less than 55 mg/dl (3.0 mmol/liter), insulin of at least 3.0 μ U/ml (18 pmol/liter), C-peptide of at least 0.6 ng/ml (0.2 nmol/liter), and proinsulin of at least 5.0 pmol/liter document endogenous hyperinsulinism; β -hydroxybutyrate levels of 2.7 mmol/liter or less and an increase in plasma glucose of at least 25 mg/dl (1.4 mmol/liter) after iv glucagon indicate mediation of the hypoglycemia by insulin (or by an IGF).
- In a patient with documented fasting or postprandial endogenous hyperinsulinemic hypoglycemia, negative screening for oral hypoglycemic agents, and no circulating insulin antibodies, conduct procedures for localizing an insulinoma. These may include computed tomography or MRI, transabdominal and endoscopic ultrasonography, and, if necessary, selective pancreatic arterial calcium injections with measurements of hepatic venous insulin levels.
- Tailor treatment to the specific hypoglycemic disorder, taking into account the burden of hypoglycemia on patient well-being and patient preferences.

2.1. Evidence

Because hypoglycemic disorders are rare in persons without diabetes, recommendations for their evaluation and management must rely largely on clinical experience. However, the implicit alternative approach to the recommendations we propose is a much less thorough clinical evaluation. Compared with this alternative, the large potential benefit of a thorough workup upgrades the quality of the evidence to moderate. Of note, however, much lower quality evidence supports the recommended strategy when compared with strategies with minor modifications or omissions.

TABLE 1. Causes of hypoglycemia in adults**Ill or medicated individual**

1. Drugs
 - Insulin or insulin secretagogue
 - Alcohol
 - Others (Table 2)
2. Critical illnesses
 - Hepatic, renal, or cardiac failure
 - Sepsis (including malaria)
 - Inanition
3. Hormone deficiency
 - Cortisol
 - Glucagon and epinephrine (in insulin-deficient diabetes mellitus)
4. Nonislet cell tumor

Seemingly well individual

5. Endogenous hyperinsulinism
 - Insulinoma
 - Functional β -cell disorders (nesidioblastosis)
 - Noninsulinoma pancreatogenous hypoglycemia
 - Post gastric bypass hypoglycemia
 - Insulin autoimmune hypoglycemia
 - Antibody to insulin
 - Antibody to insulin receptor
 - Insulin secretagogue
 - Other
6. Accidental, surreptitious, or malicious hypoglycemia

General differential diagnosis

Causes of hypoglycemia are outlined in Table 1. Drugs are the most common cause of hypoglycemia (12, 18–21). In addition to insulin and insulin secretagogues, offending drugs include alcohol (12, 19, 20) among others, as detailed below. Hypoglycemia sometimes occurs during sepsis and in other critical illnesses including renal or hepatic failure, and rarely in cortisol deficiency (12). Hypoglycemia caused by nonislet cell tumors or endogenous hyperinsulinism is rare (12–15). It can also be accidental, surreptitious, or even malicious (22). Hypoglycemia can occur as a result of hyperinsulinism in the absence of previous gastric surgery or after Roux-en-Y gastric bypass for obesity. It can also be caused by an antibody to insulin (12, 13, 15).

Classification of hypoglycemia

The traditional classification of hypoglycemia in persons without diabetes—postabsorptive (fasting)

TABLE 2. Drugs other than antihyperglycemic agents and alcohol reported to cause hypoglycemia (24)

Moderate quality of evidence (⊕⊕⊕○)

Cibenzoline
 Gatifloxacin
 Pentamidine
 Quinine
 Indomethacin
 Glucagon (during endoscopy)

Low quality of evidence (⊕○○○)

Chloroquineoxaline sulfonamide
 Artesunate/artemisin/artemether
 IGF-1
 Lithium
 Propoxyphene/dextropropoxyphene

Very low quality of evidence (⊕○○○)

Drugs with >25 cases of hypoglycemia identified
 Angiotensin converting enzyme inhibitors
 Angiotensin receptor antagonists
 β -Adrenergic receptor antagonists
 Levofloxacin
 Mifepristone
 Disopyramide
 Trimethoprim-sulfamethoxazole
 Heparin
 6-Mercaptopurine
 Drugs with <25 cases of hypoglycemia identified (see Ref. 24)

vs. postprandial (reactive) hypoglycemia—has been challenged (14). Persons with an insulinoma, who typically have postabsorptive hypoglycemia, may experience postprandial hypoglycemia, and post-gastric-bypass patients, who typically have postprandial hypoglycemia, may have symptoms when fasting. Indeed, some disorders, *e.g.* factitious hypoglycemia, are not readily classified as either postabsorptive or postprandial. Postprandial symptoms without Whipple's triad, previously called "reactive hypoglycemia," indicate a functional disorder in which symptoms are not due to hypoglycemia and for which an oral glucose tolerance test is not indicated (23). A more useful categorization for the clinician is to establish whether the patient is seemingly well or has the burden of a potentially relevant treatment or disease. With respect to the latter, it cannot be overemphasized that in any patient with hypoglycemia, mediation by a medication must be considered.

Drugs that can cause hypoglycemia

Many drugs in addition to insulin, insulin secretagogues, and alcohol have been reported to cause hypoglycemia (12–15, 18–21, 24). Many of these are listed in Table 2 (24).

Drugs, often in the setting of critical illnesses including renal failure, are the most common cause of hypoglycemia in hospitals (18). Again, insulin or insulin secretagogues are common offending drugs (18, 25), particularly when administered when enteral or parenteral nutrition is interrupted or when sensitivity to insulin is increased (*e.g.* after withdrawal of glucocorticoid therapy). Hypoglycemia is a sentinel event for many of the systems errors that compromise the safety of hospitalized patients (26). These include failure to reconcile admission orders with preadmission medications and diet, frequent transfers between hospital units, frequent travel of patients for radiological and surgical procedures and other diagnostic and therapeutic interventions, and inappropriate use of an insulin sliding scale.

Clinical evaluation

Persons with a hypoglycemic disorder present clinically with a history either of discrete spells compatible with hypoglycemia or of a serendipitously measured low plasma glucose concentration. Careful elicitation of the history of the spells, noting the specific symptoms, their timing and duration, and any aggravating and relieving factors, is essential for the formulation of a diagnostic course of action. Persons with only neurogenic symptoms (with no documented low glucose levels) are unlikely to have a hypoglycemic disorder. However, even one episode of neuroglycopenia warrants a diagnostic evaluation.

Initially, the history (including exposure to any medications), the physical examination, and a careful review of available laboratory data guide the evaluation. These will usually either provide clues to a cause of hypoglycemia or exclude hypoglycemia caused by acknowledged medications, critical illnesses, hormone deficiencies, or a nonislet cell tumor (Table 1). A test of adrenocortical function is reasonable, although adrenocortical failure is not commonly found as a cause of hypoglycemia in adults

in the absence of other clinical clues. A seemingly low plasma cortisol concentration measured during spontaneous hypoglycemia is not sufficient evidence of adrenocortical insufficiency because of the effect of recurrent hypoglycemia to shift glycemic thresholds for cortisol secretion to lower plasma glucose concentrations (10). Although hypoglycemia in patients with nonislet cell tumors is often the result of tumor overproduction of incompletely processed IGF-II (27), hypoglycemia attributed to overproduction of IGF-I has also been reported (28). Nonislet cell tumor hypoglycemia is usually, but not invariably, associated with large, clinically apparent mesenchymal tumors. The tumors typically secrete excessive amounts of pro-IGF-II. This form of IGF-II binds poorly to its binding proteins and therefore more freely penetrates tissue spaces. The total level of IGF-II may be normal, but the ratio of pro-IGF-II to IGF-II may be elevated; this can be demonstrated by chromatographic techniques, most easily and rapidly using thin layer chromatography (29). Because of suppressed GH secretion and the resulting low IGF-I levels, IGF-II to IGF-I ratios are elevated (27). Free IGF-II (or IGF-I) levels are increased (30), but these measurements are not yet generally available. Endogenous insulin secretion is suppressed appropriately in nonislet cell tumor hypoglycemia.

In a seemingly well individual, the differential diagnosis narrows to two general categories: accidental, surreptitious, or even malicious hypoglycemia and endogenous hyperinsulinism (12–15). Careful consideration of the former possibility (22) should precede a systematic assessment of the latter possibility. Pharmacy errors (*e.g.* substitution of a sulfonylurea for another medication) and medical treatment errors occur (31). Surreptitious hypoglycemia (22, 32–35) is more common in people with knowledge of, and access to, glucose-lowering medications. Malicious hypoglycemia (22, 36, 37) can be accomplished by administration of insulin or an insulin secretagogue.

Clinically, insulinoma is characterized by spells of neuroglycopenia due to endogenous hyperinsulinemic hypoglycemia occurring primarily in the fasting state but occasionally only in the postprandial period (23, 38, 39). The incidence is approximately 1 in

250,000 patient-years (40). It may occur in all ethnic groups and at any age and has a slight predominance in women. Less than 10% of patients have malignant insulinomas, have multiple tumors, or have the multiple endocrine neoplasia, type 1 (MEN-1) syndrome. The recurrence rate after surgical resection is 7% for patients without MEN-1 and 21% for those with MEN-1 (40). Recurrences before 4 yr have elapsed from the initial removal of the tumor suggest fracture of the insulinoma at the time of the original enucleation (41). Long-term survival is the rule for patients who have undergone successful insulinoma removal (40).

The noninsulinoma pancreatogenous hypoglycemia syndrome (NIPHS) is characterized by spells of neuroglycopenia due to endogenous hyperinsulinemic hypoglycemia typically, but not invariably, after a meal (42–45). There is a predominance in men. The pancreatic abnormality is diffuse islet involvement with nesidioblastosis [islet hypertrophy, sometimes with hyperplasia, with enlarged and hyperchromatic β -cell nuclei (46, 47)]. Radiological localization procedures are invariably negative. Confirmation of islet hyperfunction depends on a positive selective arterial calcium stimulation test. Amelioration of symptoms can be expected with partial pancreatectomy guided by the results of the calcium stimulation test. The frequency of NIPHS is much less than that of insulinoma.

Some persons who have undergone Roux-en-Y gastric bypass for obesity have endogenous hyperinsulinemic hypoglycemia most often due to pancreatic islet nesidioblastosis, but occasionally due to an insulinoma (48–50). With nesidioblastosis, spells of neuroglycopenia usually occur in the postprandial period and develop many months after bariatric surgery. Spells of neuroglycopenia that occur in the fasting state soon after bariatric surgery are more likely due to a preexisting insulinoma (51). The predominance of women with post-gastric-bypass hypoglycemia may reflect the gender imbalance of bariatric surgery. The precise mechanisms of hypoglycemia remain to be determined (52–54). The incidence of this disorder is unknown, but at the Mayo Clinic the number of cases exceeds, by a considerable degree, that of insulinoma. Partial pancreatectomy is recommended

for nesidioblastosis in patients who do not respond to dietary or medical (e.g. an α -glucosidase inhibitor, diazoxide, octreotide) treatments.

Hypoglycemia due to the development of antibodies to native insulin is a rare disorder reported to occur primarily among persons of Japanese or Korean ethnicity (55) and significantly less frequently in Caucasians (56). Persons with this disorder often have a history of autoimmune disease or exposure to sulfhydryl-containing drugs. Symptoms occur in the late postprandial period as insulin secreted in response to the meal and then bound to the circulating antibody dissociates from the antibody in an unregulated fashion. Clues to the diagnosis include very high measured insulin levels during hypoglycemia. That can be the result of an assay artifact caused by the antibody. The severity of hypoglycemia varies from mild, and treatable with lifestyle changes, to severe, for which no modality aside from intragastric glucose infusion has been effective. The diagnosis is readily made by the finding of high titer serum insulin antibodies. A similar hypoglycemic disorder has been described in patients who have a high capacity insulin binding monoclonal paraprotein (57).

Evaluation of hypoglycemia in seemingly well individuals

If a seemingly well patient is symptomatic when seen by the caregiver, the most expeditious diagnostic maneuver (14, 15) is to obtain plasma for the measurement of glucose, insulin, C-peptide, proinsulin, β -hydroxybutyrate, and circulating oral hypoglycemic agents (ideally all available sulfonylureas and glinides), and then to correct the hypoglycemia with the injection of 1.0 mg glucagon iv with measurement of the plasma glucose response. These data will distinguish endogenous (and exogenous) hyperinsulinism from other causes of hypoglycemia. Insulin antibodies, which need not be measured at the time of hypoglycemia, will identify insulin autoimmune hypoglycemia.

The key pathophysiological feature of endogenous hyperinsulinism is the failure of insulin secretion to fall to very low rates as plasma glucose concentrations

fall to hypoglycemic levels; hypoglycemia is the result of low rates of glucose production rather than high rates of glucose utilization (58). Thus, plasma insulin, C-peptide, and proinsulin concentrations need not be high relative to normal euglycemic values but only inappropriately high in the setting of low fasting plasma glucose concentrations (12–15). Critical diagnostic findings are plasma insulin concentrations of at least 3 $\mu\text{U}/\text{ml}$ (18 pmol/liter), plasma C-peptide concentrations of at least 0.6 ng/ml (0.2 nmol/liter), and plasma proinsulin concentrations of at least 5.0 pmol/liter when the fasting plasma glucose concentrations are below 55 mg/dl (3.0 mmol/liter) (14, 15). Ratios employing insulin and glucose have no diagnostic utility (59). These criteria assume the absence of intercurrent illnesses including renal insufficiency.

An occasional patient with an insulinoma may not fulfill these criteria even during a 72-h fast (15, 60),

and a few have plasma insulin levels below 3 $\mu\text{U}/\text{ml}$ (18 pmol/liter) during fasting hypoglycemia, but plasma C-peptide levels are usually 0.6 ng/ml (0.2 nmol/liter) or greater and plasma proinsulin levels are usually 5.0 pmol/liter or greater in the latter patients. For example, in one series the plasma insulin criterion was met in 29 of 32 patients with an insulinoma, whereas the C-peptide and proinsulin criteria were met in all 32 patients (61). Plasma β -hydroxybutyrate levels of 2.7 mmol/liter or less and an increase in the plasma glucose concentration of at least 25 mg/dl (1.4 mmol/liter) after iv glucagon, the latter indicating preserved hepatic glycogen stores, provide biological evidence of insulin (or IGF) excess (62). The findings that distinguish among the causes of hyperinsulinemic (or IGF-mediated) hypoglycemia are summarized in Table 3.

When Whipple's triad has not been documented in a patient with a history of suggestive spells and when

TABLE 3. Patterns of findings during fasting or after a mixed meal in normal individuals with no symptoms or signs despite relatively low plasma glucose concentrations (*i.e.* Whipple's triad not documented) and in individuals with hyperinsulinemic (or IGF-mediated) hypoglycemia or hypoglycemia caused by other mechanisms.

Symptoms, signs, or both	Glucose (mg/dl)	Insulin ($\mu\text{U}/\text{ml}$)	C-peptide (nmol/liter)	Proinsulin (pmol/liter)	β -Hydroxybutyrate (mmol/liter)	Glucose increase after glucagon (mg/dl)	Circulating oral hypoglycemic	Antibody to insulin	Diagnostic interpretation
No	< 55	< 3	< 0.2	< 5	> 2.7	< 25	No	No	Normal
Yes	< 55	» 3	< 0.2	< 5	\leq 2.7	> 25	No	Neg (Pos)	Exogenous insulin
Yes	< 55	\geq 3	\geq 0.2	\geq 5	\leq 2.7	> 25	No	Neg	Insulinoma, NIPHS, PGBH
Yes	< 55	\geq 3	\geq 0.2	\geq 5	\leq 2.7	> 25	Yes	Neg	Oral hypoglycemic agent
Yes	< 55	» 3	» 0.2 ^a	» 5 ^a	\leq 2.7	> 25	No	Pos	Insulin autoimmune
Yes	< 55	< 3	< 0.2	< 5	\leq 2.7	> 25	No	Neg	IGF ^b
Yes	< 55	< 3	< 0.2	< 5	> 2.7	< 25	No	Neg	Not insulin (or IGF)-mediated

Neg, negative; Pos, positive; PGBH, post gastric bypass hypoglycemia.

^a Free C-peptide and proinsulin concentrations are low.

^b Increased pro-IGF-II, free IGF-II, IGF-II/IGF-I ratio.

the appropriate tests have not been obtained during an episode of spontaneous hypoglycemia, recreation of the circumstances likely to lead to hypoglycemia should be pursued (12, 14, 15). For the patient with a history suggesting fasting hypoglycemia, this may be accomplished by withholding food, and for the patient with a history suggestive of postprandial hypoglycemia, this may be accomplished by providing the type of meal likely to cause a spell. When these maneuvers fail, the patient with suspected fasting hypoglycemia should undergo a prolonged supervised fast. This fast can be initiated as an outpatient and completed (if necessary) in hospital. The fast should be continued to the point at which Whipple's triad is documented or to a plasma glucose of less than 55 mg/dl (3.0 mmol/liter) if Whipple's triad had been documented unequivocally previously (15, 60), unless a progressive rise in β -hydroxybutyrate levels signals a negative fast (62). Plasma glucose concentrations should be measured with a precise method, not with self-monitoring of blood glucose. Most, but not all (60), patients with an insulinoma fulfill these diagnostic criteria in less than 72 h. Indeed, that occurs in less than 24 h in about two thirds, and in less than 48 h in the vast majority, of affected patients (60). The patient with a history suggestive of postprandial hypoglycemia should undergo a mixed-meal test. That meal should include the components recognized by the patient as likely to cause hypoglycemia (although a nutritional supplement formula mixed meal is sometimes used) and should be conducted over 5 h. An oral glucose tolerance test should never be used for the evaluation of suspected postprandial hypoglycemia (63). However, standards for the interpretation of the mixed-meal test have not been established. Current clinical usage is to apply the above criteria developed under fasting conditions (14) to the results from a mixed-meal challenge. Finally, for the patient requiring iv glucose to prevent hypoglycemia, diagnostic data can be obtained by serial sampling, under close supervision, after temporary discontinuation of glucose infusion.

A patient with documented Whipple's triad, inappropriately high plasma insulin, C-peptide, and proinsulin levels; and no detectable oral hypoglycemic agent levels during fasting

hypoglycemia; and no circulating antibodies to insulin probably has an insulinoma (12–15). Nonetheless, accidental, surreptitious, or malicious hypoglycemias are difficult entities to diagnose. These diagnoses depend on a high degree of clinical suspicion and pursuit of potential sources of offending agents (including inspection of the patient's medications). There are, however, causes of fasting endogenous hyperinsulinemic hypoglycemia other than an insulinoma. Some patients do not have an insulinoma but have a diffusely expanded islet cell mass (46, 47, 64, 65). That is often termed nesidioblastosis, although the histological finding of islets budding from pancreatic ducts is not invariably present (46, 47). Nesidioblastosis due to prolonged factitious use of a sulfonylurea has been reported (66). Although seemingly convincing cases have been reported (see Ref. 67), ectopic insulin secretion must be very rare. Similarly, hyperinsulinemic hypoglycemia linked to a mutation of the insulin receptor (68) and exercise-induced hyperinsulinemia (69) are rare syndromes. Finally, rare patients with fasting hypoglycemia and appropriately suppressed C-peptide levels but inappropriately elevated insulin levels have an agonist antibody to the insulin receptor (70). In that instance hypoglycemia is the result of the action of the antibody to stimulate insulin receptors; somewhat elevated insulin levels are thought to be the result of decreased clearance of insulin. Typically, the affected patient is African-American, usually female, often with an associated autoimmune disease.

The diagnosis of an insulinoma requires convincing clinical and biochemical evidence before any attempt to regionalize or localize the tumor (12–15). Although the results with a given method reflect the experience and expertise with that method at a given center, computed tomography, MRI, and transabdominal ultrasonography detect most insulinomas (71–73). They also often detect metastases in the less than 10% of insulinomas that are malignant. However, because insulinomas are often less than 1.0 cm in diameter (73), negative imaging does not exclude an insulinoma. Computed tomography detects 70 to 80% and MRI about 85% (73). Somatostatin receptor scintigraphy is reported

to detect insulinomas in approximately half of affected patients (74), although a sensitivity of 80% has been reported (75). Endoscopic pancreatic ultrasonography, with the option of fine-needle aspiration of a detected tumor, is invasive but in some centers has a sensitivity greater than 90% (76, 77). With the combination of noninvasive and selected invasive modalities (particularly endoscopic ultrasound), most insulinomas are localized preoperatively (72, 78). Selective pancreatic arterial calcium injections, with an endpoint of a greater than 2-fold increase in hepatic venous insulin levels over baseline (79, 80) [or perhaps a greater than 5-fold increase with contemporary specific insulin assays (81)] regionalizes insulinomas with high sensitivity (81, 82). That invasive procedure can help to regionalize an insulinoma when imaging is equivocal or negative. However, it is the procedure of choice for confirming noninsulinoma pancreatogenous hypoglycemia (15, 43–45) and post Roux-en-Y gastric bypass hypoglycemia (48–50) because standard imaging is negative in those disorders. The relative utility of positron emission tomography in the noninvasive localization of insulinomas remains to be determined, although that with [¹⁸F]dihydroxyphenylalanine is promising (83). Intraoperative pancreatic ultrasonography almost invariably localizes tumors that are not apparent to the experienced pancreatic surgeon.

Prevention of recurrent hypoglycemia requires treatment that corrects or circumvents the hypoglycemic mechanism (12–15) (Table 1, page 9). Offending drugs can be discontinued or their dosage reduced. Underlying critical illnesses can often be treated. Cortisol can be replaced. Surgical, radiotherapeutic, or chemotherapeutic reduction of the mass of a nonislet cell tumor can alleviate hypoglycemia even if the tumor cannot be cured; glucocorticoid, GH, or occasionally octreotide administration may alleviate hypoglycemia in such patients. Surgical resection of a benign insulinoma is curative. Medical treatment with diazoxide, octreotide, or both can be used if resection of an insulinoma is not possible and in patients with a nontumor β -cell disorder, although partial pancreatectomy may be required. Treatment of

TABLE 4. Suggested protocol for a prolonged diagnostic fast

Date the onset of the fast as the time of the last food intake. Discontinue all nonessential medications.

Allow the patient to drink calorie-free beverages. Ensure that the patient is active during waking hours.

Collect samples for plasma glucose, insulin, C-peptide, proinsulin, and β -hydroxybutyrate every 6 h until the plasma glucose concentration is less than 60 mg/dl (3.3 mmol/liter); at that point the frequency of sampling should be increased to every 1 to 2 h.

Samples for plasma insulin, C-peptide, and proinsulin should be sent for analysis only in those samples in which the plasma glucose concentration is less than 60 mg/dl (3.3 mmol/liter).

End the fast when the plasma glucose concentration is less than 45 mg/dl (2.5 mmol/liter) and the patient has symptoms and/or signs of hypoglycemia (or if 72 h have elapsed without symptoms). The decision to end the fast before 72 h should not be based on a low plasma glucose concentration alone, in the absence of symptoms or signs, because some healthy individuals, especially women and children, have low glucose levels during prolonged fasting. Alternatively, the fast can be ended when the plasma glucose concentration is less than 55 mg/dl (3.0 mmol/liter) without symptoms or signs if Whipple's triad was documented unequivocally on a prior occasion.

A low plasma glucose concentration is a necessary, albeit not in itself sufficient, finding for the diagnosis of hypoglycemia. Therefore, the decision to end the fast should be based on laboratory-measured plasma glucose concentrations, not those estimated with a point-of-care glucose monitor. If it is judged necessary to treat urgently because of severe symptoms, obtain samples for all of the following before administering carbohydrates.

At the end of the fast, collect samples for plasma glucose, insulin, C-peptide, proinsulin, β -hydroxybutyrate, and oral hypoglycemia agents, and then inject 1.0 mg of glucagon iv and measure plasma glucose 10, 20, and 30 min later. (Insulin antibodies should be measured, but not necessarily during hypoglycemia.)

autoimmune hypoglycemias (e.g. with a glucocorticoid or another immunosuppressant medication) is problematic, but these disorders may be self-limited, at least in Asians. In patients with NIPHS or post gastric bypass hypoglycemia medical therapy with frequent feedings, an α -glucosidase inhibitor, diazoxide, and octreotide are occasionally effective. Partial pancreatectomy often provides amelioration. Failing these treatments, provision of exogenous

TABLE 5. Suggested protocol for a mixed-meal diagnostic test

Perform the test after an overnight fast. Hold all nonessential medications.

Use a mixed meal similar to that which the patient reports has caused symptoms (or use a commercial formula mixed meal).

Collect samples for plasma glucose, insulin, C-peptide, and proinsulin before ingestion and every 30 min through 300 min after ingestion of the meal.

Observe the patient for symptoms and/or signs of hypoglycemia and ask the patient to keep a written log of all symptoms, timed from the start of meal ingestion. If possible, avoid treatment until the test is completed.

A low plasma glucose concentration is a necessary, albeit not in itself sufficient, finding for a diagnosis of hypoglycemia. Therefore, the mixed-meal test should be interpreted on the basis of laboratory-measured plasma glucose concentrations, not those estimated with a point-of-care glucose monitor. If it is judged necessary to treat before 300 min because of severe symptoms, obtain samples for all of the following before administering carbohydrates.

Samples for plasma insulin, C-peptide, and proinsulin should be sent for analysis only in those samples in which plasma glucose is less than 60 mg/dl (3.3 mmol/liter), and a sample for measurement of oral hypoglycemic agents should be obtained, if Whipple's triad is demonstrated. In that case, antibodies to insulin should also be measured.

glucose with large doses of uncooked cornstarch or even intragastric glucose infusion may be necessary.

2.1. Values

The decision to undergo invasive localization procedures and partial pancreatectomy places a higher value on achieving long-term remission of hypoglycemia and a lower value on avoiding invasive diagnostic procedures and avoiding the potential downsides of pancreatectomy (including diabetes, bleeding, infection, and death). Some patients with mild hypoglycemia who are able to cope with minimal interventions may prefer to avoid invasive evaluations and surgery. Severely affected patients may prefer a treatment approach that includes precise localization of the insulin-producing lesion and partial pancreatectomy.

2.1. Remarks

Suggested protocols for a prolonged diagnostic fast and for a mixed-meal diagnostic test are shown in Tables 4 and 5, respectively.

3.0. EVALUATION AND MANAGEMENT OF HYPOGLYCEMIA IN PERSONS WITH DIABETES MELLITUS

Background

Treatment-induced hypoglycemia is the limiting factor in the glycemic management of diabetes (12, 16, 84). It causes recurrent morbidity in most persons with type 1 diabetes mellitus (T1DM) and in many with advanced (*i.e.* absolute endogenous insulin-deficient) type 2 diabetes mellitus (T2DM), and it is sometimes fatal. It precludes maintenance of euglycemia over a lifetime of diabetes and thus full realization of the established microvascular and potential macrovascular and other benefits of long-term glycemic control. It compromises physiological and behavioral defenses against subsequent falling plasma glucose concentrations and thus causes a vicious cycle of recurrent hypoglycemia. Because of steady improvements in the glycemic management of diabetes, it is possible both to improve glycemic control and to minimize the risk of hypoglycemia in many patients (12, 16, 84–86). Nonetheless, the problem of hypoglycemia has not been solved. Solution of that problem will require glucose-regulated insulin replacement or secretion until the prevention and cure of diabetes is achieved (16).

Hypoglycemia in diabetes is fundamentally the result of treatments that raise insulin levels and thus lower plasma glucose concentrations (12, 16, 84, 85). Those treatments include insulin or insulin secretagogues such as a sulfonylurea or a nonsulfonylurea insulin secretagogue (*e.g.* nateglinide or repaglinide). Early in its course, T2DM may respond to drugs that do not

raise insulin levels at normal or low plasma glucose concentrations and, therefore, should not cause hypoglycemia. Those include a biguanide (metformin), which nonetheless has been reported to cause hypoglycemia (87); thiazolidinediones (pioglitazone, rosiglitazone); α -glucosidase inhibitors (acarbose, miglitol); glucagon-like peptide-1 receptor agonists (exenatide, liraglutide); and dipeptidyl peptidase-IV inhibitors (sitagliptin, vildagliptin). However, these drugs can increase the risk of hypoglycemia when used with an insulin secretagogue (see Ref. 88) or insulin.

Physiology and pathophysiology

Hypoglycemia is typically the result of the interplay of relative or absolute therapeutic insulin excess and compromised physiological and behavioral defenses against falling plasma glucose concentrations in T1DM and long-standing T2DM (12, 16, 84, 85).

Relative, or even absolute, insulin excess must occur from time to time during treatment with an insulin secretagogue or insulin because of the pharmacokinetic imperfections of these therapies. Insulin excess of sufficient magnitude can, of course, cause hypoglycemia. Nonetheless, as discussed below, the incidence of hypoglycemia is relatively low (at least with current glycemic goals), even during treatment with insulin, early in the course of T2DM when glycemic defenses are intact. However, the risk increases progressively over time and approaches that in T1DM as glycemic defenses become compromised.

As discussed earlier, the critical physiological defenses against falling plasma glucose concentrations include: 1) decrements in insulin secretion; 2) increments in glucagon secretion; and, in the absence of the latter, 3) increments in epinephrine secretion (6, 7, 12). The behavioral defense is the ingestion of carbohydrates (6, 7, 12). That behavior is prompted by the perception of symptoms, largely the neurogenic symptoms (4) mediated by sympathetic neural activation (5).

All of these defenses, not just insulin secretion, are compromised in T1DM and in long-standing T2DM (12, 16, 89, 90). In fully developed T1DM, circulating insulin levels do not decrease as plasma glucose levels decline. Furthermore, in the absence of a β -cell

signal, including a decrease in intraislet insulin (91), the α -cell glucagon response to hypoglycemia is also lost (92). In the absence of the first (insulin) and second (glucagon) defenses, persons with T1DM are critically dependent on the third defense, epinephrine secretion. However, the epinephrine response to hypoglycemia is often attenuated (8, 12, 16, 89, 93, 94). Through mechanisms yet to be clearly defined but generally thought to reside in the brain (12, 16, 85, 95), the glycemic threshold for sympathoadrenal activation is shifted to lower plasma glucose concentrations by recent antecedent hypoglycemia, as well as by prior exercise and by sleep (12, 16, 89, 90, 95–97). In the setting of absent decrements in insulin and absent increments in glucagon as plasma glucose levels fall in response to therapeutic hyperinsulinemia, the attenuated epinephrine response causes the clinical syndrome of defective glucose counterregulation that has been shown to increase the risk of severe hypoglycemia by 25-fold (98) or even more (99). In addition, the attenuated sympathetic neural response causes the clinical syndrome of hypoglycemia unawareness—impairment or even loss of the warning symptoms that previously prompted the behavioral defense, *i.e.* the ingestion of carbohydrates. Hypoglycemia unawareness is associated with a 6-fold increased risk for severe hypoglycemia (100).

The concept of hypoglycemia-associated autonomic failure (HAAF) in diabetes is based on pivotal findings in nondiabetic individuals (97) and patients with T1DM (101) and was first documented in T1DM (89). It posits that recent antecedent hypoglycemia [or prior exercise or sleep (16)] causes both defective glucose counterregulation (by reducing the epinephrine response in the setting of absent insulin and glucagon responses) and hypoglycemia unawareness (largely by reducing the sympathetic neural response and the resulting neurogenic symptoms) and, thus, a vicious cycle of recurrent hypoglycemia (12, 16). Perhaps the most compelling support for the clinical impact of HAAF in T1DM is the finding that as little as 2–3 wk of scrupulous avoidance of treatment-induced hypoglycemia reverses hypoglycemia unawareness, and improves the reduced epinephrine component of defective glucose

counterregulation in most affected patients (102–105).

More recently, the concept of HAAF (12, 16, 89) has been extended to patients with long-standing T2DM and absolute insulin deficiency (90). As just discussed, HAAF stems fundamentally from β -cell failure. Initially, T2DM is characterized by insulin resistance and only relative hypoinsulinemia, conditions that allow decrements in insulin and increments in glucagon while plasma glucose concentrations fall. Over time,

however, absolute endogenous insulin deficiency develops (87). Thus, as patients approach the insulin-deficient end of the spectrum of T2DM (118), typically over many years, their insulin and glucagon responses to falling glucose levels are lost (90), as in T1DM. Furthermore, their glycemic thresholds for sympathoadrenal responses are shifted to lower plasma glucose concentrations by recent antecedent hypoglycemia (90), as in T1DM. Thus, patients with long-standing T2DM are also at risk for HAAF.

TABLE 6. Event rates for severe hypoglycemia (requiring the assistance of another person) expressed as episodes per 100 patient-years

First author, year (Ref.)	n	Event rate	Comment
T1DM			
UK Hypoglycaemia Study Group, 2007 (119)	57 ^a	320	Prospective multicenter study
	50 ^b	110	
MacLeod, 1993 (120)	544	170	Retrospective clinic survey, randomly selected sample
Donnelly, 2005 (121)	94	115	Prospective study, population-based random sample
Reichard and Pihl, 1994 (122)	48	110	Clinical trial, intensive insulin group
DCCT Research Group, 1993 (123)	711	62	Clinical trial, intensive insulin group
T2DM			
MacLeod, 1993 (120)	56	73	Retrospective clinic survey, randomly selected sample
UK Hypoglycaemia Study Group, 2007 (119)	77 ^c	70	Prospective multicenter study
	89 ^d	10	
Akram, 2006 (124)	401	44	Retrospective clinic survey
Donnelly, 2005 (121)	173	35	Prospective study, population-based random sample
Henderson, 2003 (125)	215	28	Retrospective clinic survey, randomly selected sample
Murata, 2005 (126)	344	21	Prospective study, random Veterans Affairs sample
Saudek, 1996 (127)	62	18 ^e	Clinical trial, multiple insulin injection group
Gürlek, 1999 (128)	114	15	Retrospective clinic survey
Abraira, 1995 (129)	75	3	Clinical trial, intensive insulin group
Yki-Järvinen, 1999 (130)	88	0	Clinical trial, initial insulin therapy
Ohkubo, 1995 (131)	52	0	Clinical trial, initial insulin therapy

Studies covering at least 1 yr, involving at least 48 patients, and reporting severe hypoglycemia event rates are included.

a Insulin treatment for > 15 yr.

b Insulin treatment for < 5 yr.

c Insulin treatment for > 5 yr.

d Insulin treatment for < 2 yr.

e Definite (8 per 100 patient-years) plus suspected (10 per 100 patient-years).

There may well be as yet unrecognized functional, and thus potentially reversible, causes of a reduced sympathoadrenal response to hypoglycemia, the key feature of HAAF, in addition to recent antecedent hypoglycemia, prior exercise, and sleep. There may also be a structural, irreversible component. For example, the reduced sympathoadrenal response to hypoglycemia is not fully normalized after scrupulous avoidance of hypoglycemia (103–105) or during insulin independence after successful pancreatic islet transplantation (106). Furthermore, the sympathoadrenal response to hypoglycemia is reduced to a greater extent in patients with classical diabetic autonomic neuropathy (107, 108). Finally, a reduced plasma metanephrine response to hypoglycemia in patients with HAAF suggests a reduced adrenomedullary epinephrine secretory capacity (109). Such a structural component would be consistent with the evidence of a relationship between severe hypoglycemia and a long duration of T1DM (see Ref. 110).

In summary, although the pathophysiology of glucose counterregulation is the same in T1DM and T2DM, it develops rapidly in T1DM (as absolute insulin deficiency develops rapidly) but slowly in T2DM (as absolute insulin deficiency develops slowly). This difference in the time course of the evolution of HAAF plausibly explains, at least in part, the relatively low frequency of treatment-induced hypoglycemia early in the course of T2DM and the higher frequency of treatment-induced hypoglycemia, approaching that in T1DM, later in T2DM (discussed below). That pathophysiology also provides insight into the risk factors for, and the prevention of, hypoglycemia in T2DM as well as in T1DM.

Incidence and impact

Hypoglycemia is a fact of life for most persons with T1DM (12, 16). The average patient with T1DM suffers two episodes of symptomatic hypoglycemia per week—thousands of such episodes over a lifetime of diabetes—and one episode of temporarily disabling hypoglycemia, often with seizure or coma, per year. An estimated 2–4% of people with T1DM die from hypoglycemia (12, 111).

Reported severe hypoglycemia event rates in patients with T1DM (119–123) and those with T2DM (119–121, 124–131) are summarized in Table 6.

Although prolonged, profound hypoglycemia can cause neurological damage and thus brain death, the mechanism(s) of sudden death during less marked hypoglycemia is unknown but may involve a cardiac arrhythmia (6). Hypoglycemia causes a transiently prolonged corrected QT interval, as well as increased QT dispersion, an effect thought to be mediated by the sympathoadrenal response to hypoglycemia (112, 113). Furthermore, a prolonged corrected QT interval has been found to be associated with episodes of nocturnal hypoglycemia in patients with T1DM (114, 115). Thus, it is reasonable to suggest (112–115) that a fatal arrhythmia triggered by hypoglycemia might explain the “dead in bed syndrome,” an unexpected death of a person with T1DM occurring during the night (116).

In the Action to Control Cardiovascular Risk in Diabetes (ACCORD) study, 10,251 patients with T2DM at high cardiovascular risk (but with no history of frequent or recent serious hypoglycemic events) were randomized to either intensive glycemic therapy with an HbA_{1c} goal of less than 6.0% or to standard glycemic therapy (117). After a median follow-up of 3.4 yr, with stable median HbA_{1c} levels of 6.4 and 7.5%, respectively, intensive glycemic therapy was discontinued because 5.0% of the patients in the intensive therapy group, compared with 4.0% of those in the standard therapy group, had died (hazard ratio, 1.22; 95% confidence interval, 1.01–1.46; *P* = 0.04). The cause of excess mortality during intensive glycemic therapy in ACCORD is not known (117). It could have been chance. It could have been the result of a nonglycemic effect of the intensive therapy regimen (*e.g.* an adverse effect of one or more of the drugs, weight gain, or something else) although none was apparent. Nonetheless, the most plausible cause of excess mortality during intensive therapy in ACCORD is iatrogenic hypoglycemia: 1) median glycemia (HbA_{1c}) was intentionally and demonstrably lower in the intensive glycemic therapy group; 2) lower HbA_{1c} levels are known to be associated with a higher frequency of hypoglycemia in T2DM (117, 132); indeed, the

prevalence of severe hypoglycemia was more than 3-fold higher in the intensive therapy group in ACCORD (117); 3) hypoglycemia can be fatal in T2DM (6); that includes sudden, presumably cardiac arrhythmic, death; and 4) more patients died in the intensive glycemic therapy group (117). Another randomized controlled trial of aggressive glycemic therapy in T2DM, the VA Diabetes Trial was reported at the 2008 American Diabetes Association (ADA) meeting. The incidence of severe hypoglycemia was higher in the intensively treated group, and a history of severe hypoglycemia was a significant predictor of cardiovascular death.

Overall, hypoglycemia is less frequent in T2DM than in T1DM (12, 16). However, hypoglycemia becomes progressively more limiting to glycemic control over time in T2DM (118). The UK Hypoglycemia Study Group reported that in patients with T2DM treated with insulin for less than 2 yr or more than 5 yr, the prevalence of severe hypoglycemia was 7 and 25%, and the incidence was 10 and 70 episodes per 100 patient-years, respectively (119). The pattern for self-treated hypoglycemia was similar (119). Thus, whereas the risk of hypoglycemia is relatively low in the first few years of insulin treatment, that risk increases substantially later in the course of T2DM.

Reported hypoglycemia event rates in diabetes are generally underestimates because of the difficulty of ascertainment. Asymptomatic episodes of hypoglycemia will be missed unless incidentally detected by routine self-monitoring of blood glucose or by continuous glucose sensing. Furthermore, symptomatic episodes may not be recognized as such because the symptoms of hypoglycemia are nonspecific. Even if they are recognized, they are often not long remembered and therefore may not be reported at periodic clinic visits. Severe hypoglycemic episodes—those sufficiently disabling that they require the assistance of another person—are more dramatic events that are more likely to be recalled (by the patient or by a close associate). Thus, although they represent only a small fraction of the total hypoglycemic experience, estimates of severe hypoglycemia event rates are the most reliable. In addition, hypoglycemia event rates determined prospectively, particularly if hypoglycemia is a

primary study endpoint, should be more reliable than those determined retrospectively. Although the incidence of hypoglycemia (Table 6) is often determined from clinical treatment trials, there are limitations to that approach. First, hypoglycemia is not a primary outcome of such trials, and therefore the extent of data collection concerning hypoglycemia varies. For example, much was learned about hypoglycemia in T1DM in the Diabetes Control and Complications Trial (133), but the hypoglycemia event rates in T2DM in the United Kingdom Prospective Diabetes Study are not known (132). Second, insulin treatment trials in T2DM are often conducted in patients just failing oral hypoglycemic agent therapy and naive to insulin therapy. Such patients are at relatively low risk for hypoglycemia as discussed earlier. Third, the therapeutic goals in clinical trials are often different from those agreed upon between patients and health care providers in clinical practice. Thus, it is important to consider evidence from prospective, population-based studies focused on hypoglycemia.

The population-based, prospective study of Donnelly *et al.* (121) indicates that the overall hypoglycemia event rates in insulin-treated patients with T2DM are approximately one third of those in patients with T1DM. The rates for any hypoglycemia were approximately 4300 per 100 patient-years in T1DM and approximately 1600 per 100 patient-years in T2DM. The rates for severe hypoglycemia were 115 per 100 patient-years in T1DM and 35 per 100 patient-years in T2DM. Furthermore, in population-based studies from hospital regions with known T1DM and T2DM incidences, event rates for severe hypoglycemia requiring emergency medical treatment in insulin-treated T2DM were approximately 40% (134) and approximately 100% (135) of those in T1DM. Because the prevalence of T2DM is approximately 20-fold greater than that of T1DM and because many patients with T2DM ultimately require treatment with insulin, these data suggest that most episodes of hypoglycemia, including severe hypoglycemia, occur in persons with T2DM.

Recommendation

3.1. We suggest that persons with diabetes become concerned about the possibility of developing hypoglycemia when the self-monitored blood glucose concentration is falling rapidly or is no greater than 70 mg/dl (3.9 mmol/liter) (2 | ⊕○○○).

3.1. Evidence

The ADA Workgroup on Hypoglycemia recommended that persons with drug-treated diabetes become concerned about developing hypoglycemia at a plasma glucose concentration of 70 mg/dl (3.9 mmol/liter) or less (136). That value approximates the lower limit of the postabsorptive plasma glucose concentration range and the glycemic threshold for activation of physiological glucose counterregulatory mechanisms (7), and it is low enough to reduce glycemic defenses against subsequent hypoglycemia (137) in nondiabetic individuals. It is higher than the glucose levels required to produce symptoms of hypoglycemia [~55 mg/dl (3.0 mmol/liter)] or to impair brain function in nondiabetic individuals (6, 7) and substantially higher than those that do so in persons with well-controlled diabetes (6–8), although persons with poorly controlled diabetes sometimes become symptomatic at somewhat higher glucose levels (8, 9). Thus, use of a 70 mg/dl (3.9 mmol/liter) plasma glucose cutoff generally gives the patient time to take action to prevent a symptomatic hypoglycemic episode. Also, in practice, self-monitoring of blood glucose is usually done with devices that are not precise analytical instruments, particularly at low plasma glucose levels (138), and the recommended cutoff value provides some margin for their inaccuracy. The ADA Workgroup also recommended a classification of hypoglycemia—severe, documented symptomatic, asymptomatic, probable symptomatic, and relative hypoglycemia—in diabetes (136) (Table 7).

Persons with diabetes typically track their glucose levels with intermittent self-monitoring of blood glucose. However, that provides a glucose estimate at only one point in time and therefore does not indicate whether glucose levels are rising, stable, or

TABLE 7. ADA Workgroup on Hypoglycemia classification of hypoglycemia in persons with diabetes (136)

Severe hypoglycemia. An event requiring assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions. Plasma glucose measurements may not be available during such an event, but neurological recovery attributable to the restoration of plasma glucose to normal is considered sufficient evidence that the event was induced by a low plasma glucose concentration.

Documented symptomatic hypoglycemia. An event during which typical symptoms of hypoglycemia are accompanied by a measured plasma glucose concentration \leq 70 mg/dl (3.9 mmol/liter).

Asymptomatic hypoglycemia. An event not accompanied by typical symptoms of hypoglycemia but with a measured plasma glucose concentration \leq 70 mg/dl (3.9 mmol/liter).

Probable symptomatic hypoglycemia. An event during which symptoms typical of hypoglycemia are not accompanied by a plasma glucose determination (but that was presumably caused by a plasma glucose concentration \leq 70 mg/dl [3.9 mmol/liter]).

Relative hypoglycemia. An event during which the person with diabetes reports any of the typical symptoms of hypoglycemia and interprets those as indicative of hypoglycemia, with a measured plasma glucose concentration $>$ 70 mg/dl (3.9 mmol/liter) but approaching that level.

falling toward hypoglycemia. That problem is being addressed by the development of technologies for continuous glucose sensing. Those technologies are as yet only evolving (139–142). It is hoped that they will lead to closed-loop insulin replacement in the not too distant future (143). Nonetheless, although these devices are promising, compelling evidence that they reliably assist patients in preventing hypoglycemia is needed.

Recommendation

3.2. Given the established long-term microvascular benefits of glycemic control, we recommend that the therapeutic glycemic goal be the lowest mean glycemia (e.g. HbA_{1c}) that can be accomplished safely in a given patient at a given point in the progression of that individual patient's diabetes (1 | ⊕⊕⊕⊕).

3.2. Evidence

Randomized controlled trials have established that intensive glycemic therapy prevents or delays the microvascular complications—retinopathy, nephropathy, and neuropathy—of diabetes (122, 123, 131, 144, 145), albeit at the expense of an increased frequency of hypoglycemia (117, 118, 122, 123, 132, 133, 144, 145). It also appears to reduce the frequency of macrovascular complications in T1DM (146, 147). Recent relatively short-term randomized controlled trials have not demonstrated a macrovascular benefit of intensive glycemic therapy in T2DM (117, 148). However, they do not exclude that possibility if glycemic control could be accomplished safely over a longer period of time. In any event, given the established microvascular benefit of improved glycemic control (122, 123, 131, 144, 145, 148), the recommendation that plasma glucose levels be held as close to the nondiabetic range as safely possible in persons with diabetes (123) is now generally accepted (149). For example, the ADA recommends an HbA_{1c} level as low as can be accomplished safely in an individual patient and generally below 7.0% (150). Nonetheless, there is substantial long-term benefit from reducing HbA_{1c} from higher to lower levels, although still above recommended levels (151, 152). However, the caregiver should be concerned about the possibility of hypoglycemia in a patient with an unusually low HbA_{1c}.

3.2. Values

Obviously, the practical difficulty here is the qualifier *safely*. The recommended glycemic goal of near euglycemia is a compromise necessitated by the barrier of treatment-induced hypoglycemia. With currently available treatments, including insulin, that goal can be accomplished with some degree of safety [*i.e.* the absence of severe hypoglycemia (Table 7)] in many patients, albeit with considerable patient and caregiver effort and expense. In other patients with T1DM or T2DM, it cannot be accomplished safely. Furthermore, some patients place a very high value on avoiding hypoglycemia. Thus, glycemic goals need to be individualized (149, 150). Nonetheless, the reality or the possibility of hypoglycemia should not be

used as an excuse for poor glycemic control in persons with diabetes.

Recommendation

3.3. We recommend that the prevention of hypoglycemia in diabetes involve addressing the issue in each patient contact and, if hypoglycemia is a problem, making adjustments in the regimen based on review and application of the principles of intensive glycemic therapy—diabetes self-management (supported by education and empowerment), frequent self-monitoring of blood glucose, flexible and appropriate insulin or insulin secretagogue regimens, individualized glycemic goals, and ongoing professional guidance and support—and consideration of each of the known risk factors for hypoglycemia (1 | ⊕⊕⊕⊕).

3.3. Evidence

It is, of course, preferable to prevent, rather than to treat, hypoglycemia in persons with diabetes. Because prevention of hypoglycemia, as compared with a reactive approach, is much more likely to avoid serious adverse effects of recurrent episodes of hypoglycemia, we upgraded the quality of the evidence in support of this recommendation, which starts as low, to moderate. The prevention of hypoglycemia requires the practice of hypoglycemia risk factor reduction (12, 16, 85): 1) acknowledging the problem; 2) applying the principles of aggressive glycemic therapy of diabetes; 3) considering the conventional risk factors (Table 8); and 4) considering the risk factors indicative of HAAF in diabetes (Table 8).

First, the issue of hypoglycemia should be addressed in every contact with patients with drug-treated diabetes, particularly those treated with an insulin secretagogue or insulin. Patient concerns about the reality, or the possibility, of hypoglycemia can be a barrier to glycemic control. It is also helpful to seek input from close associates of the patient because they may have observed clues to episodes of hypoglycemia not recognized by the patient. Even if no concerns are expressed, critical examination of the self-monitoring of blood glucose record (or continuous glucose sensing data), preferably by downloading the data, may disclose that hypoglycemia is a problem.

TABLE 8. Risk factors for hypoglycemia in diabetes**Conventional risk factors—relative or absolute insulin excess**

1. Insulin or insulin secretagogue doses are excessive, ill-timed, or of the wrong type.
2. Exogenous glucose delivery is decreased (e.g. after missed meals and during the overnight fast).
3. Glucose utilization is increased (e.g. during exercise).
4. Endogenous glucose production is decreased (e.g. after alcohol ingestion).
5. Sensitivity to insulin is increased (e.g. after weight loss, an increase in regular exercise or improved glycemic control, and in the middle of the night).
6. Insulin clearance is decreased (e.g. with renal failure).

Risk factors for hypoglycemia-associated autonomic failure

1. Absolute endogenous insulin deficiency.
2. A history of severe hypoglycemia, hypoglycemia unawareness, or both as well as recent antecedent hypoglycemia, prior exercise, and sleep.
3. Aggressive glycemic therapy *per se* (lower HbA_{1c} levels, lower glycemic goals, or both).

Second, if hypoglycemia is a problem, the principles of intensive glycemic therapy should be considered and applied. These principles include: 1) diabetes self-management (supported by education and empowerment); 2) frequent self-monitoring of blood glucose (and perhaps in some instances continuous glucose sensing); 3) flexible and appropriate insulin (and other drug) regimens; 4) individualized glycemic goals; and 5) ongoing professional guidance and support.

Diabetes self-management (supported by education and empowerment) is fundamentally important (153, 154). As the therapeutic regimen becomes progressively more complex—early in T1DM and later in T2DM—the success of glycemic management becomes progressively more dependent on the management decisions and skills of a well-informed patient. In addition, frequent self-monitoring of blood glucose data can reasonably be expected to provide insight leading to rational modifications of the therapeutic regimen (141), although additional

critical evidence on that point is needed. The emerging technology of continuous glucose sensing is conceptually attractive, but its clinical utility has not been documented (155–158). As in T1DM, in T2DM the use of long-acting basal (glargine, detemir) and rapid-acting prandial (lispro, aspart, glulisine) insulin analogs can at least minimize the risk of nocturnal hypoglycemia (159–162). Indeed, recent systematic reviews have concluded that the use of long-acting basal insulin analogs reduces the incidence of overall, symptomatic, and nocturnal hypoglycemia in T2DM and T1DM (159–161), and the use of rapid-acting prandial insulin analogs reduces nocturnal hypoglycemia in T1DM (159).

Based on their experience and knowledge of the literature, some authorities have concluded that continuous sc insulin infusion (CSII) with a rapid-acting insulin analog both improves glycemic control and reduces the rate of severe hypoglycemia compared with multiple daily injection (MDI) insulin therapy (see Ref. 163). A recent systematic review of 15 randomized trials (13 in T1DM) comparing CSII with MDI, published since 2002 and conducted mostly in patients with elevated end-of-study HbA_{1c} levels, found statistical trends favoring CSII but no clear clinical benefits of using CSII rather than MDI in terms of mild, nocturnal, or severe hypoglycemia in T1DM and T2DM (164).

Among the commonly used sulfonylureas, glyburide (glibenclamide) is most often associated with hypoglycemia (165, 166).

With respect to glycemic goals, the generic goal is an HbA_{1c} level as low as can be accomplished safely (150). Nonetheless, as mentioned earlier, there is substantial long-term benefit from reducing HbA_{1c} from higher to lower, although still above recommended, levels (151, 152). Again, glycemic goals should be individualized (149, 150).

Ongoing professional guidance and support are best provided in a chronic care model, a system of long-term diabetes care that differs fundamentally from the traditional more or less acute care model of occasional physician outpatient visits (155, 167). Such a system is organized and conducted by a diabetes care team that includes, in addition to a physician, professionals

trained in, and dedicated to, translation of the ever-evolving principles of contemporary diabetes care into practical diabetes management in individual patients. It emphasizes improvement of self-management by patients. It involves initial and ongoing teaching and application of empirical therapeutic strategies tailored to the individual patient at a given stage in his or her diabetes. It also involves contacts with patients with the use of modern technologies at various frequencies relevant to the individual patient. It requires application of computer-based methods to analyze key patient data, such as self-monitoring of blood glucose or online glucose sensing values, critically and to provide action prompts to caregivers.

Finally, the prevention of hypoglycemia involves consideration of both the conventional risk factors and those indicative of compromised physiological and behavioral defenses against falling plasma glucose concentrations (Table 8).

Recommendations

3.4. We recommend that both the conventional risk factors and those indicative of compromised defenses against hypoglycemia be considered in a patient with recurrent treatment-induced hypoglycemia (1 | ⊕⊕⊕⊕). The conventional risk factors are excessive or ill-timed dosing of, or wrong type of, insulin or insulin secretagogue, and conditions under which exogenous glucose delivery or endogenous glucose production is decreased, glucose utilization is increased, sensitivity to insulin is increased, or insulin clearance is decreased. Compromised defenses against hypoglycemia are indicated by the degree of endogenous insulin deficiency, a history of severe hypoglycemia, hypoglycemia unawareness, or both as well as recent antecedent hypoglycemia, prior exercise or sleep, and lower glycemic goals *per se*.

3.5. With a history of hypoglycemia unawareness (*i.e.* recurrent hypoglycemia without symptoms), we recommend a 2- to 3-wk period of scrupulous avoidance of hypoglycemia, with the anticipation that awareness of hypoglycemia will return in many patients (1 | ⊕⊕○○).

3.6. Unless the cause is easily remediable, we recommend that an episode of severe hypoglycemia should lead to a fundamental review of the treatment regimen and the glycemic goals (1 | ⊕⊕⊕⊕).

3.4.–3.6. Evidence

The conventional risk factors for hypoglycemia in diabetes (12, 16, 84, 85) are based on the premise that relative or absolute hyperinsulinemia is the sole determinant of risk. They include insulin or insulin secretagogue doses that are excessive, ill-timed, or of the wrong type and conditions in which exogenous glucose delivery or endogenous glucose production is decreased, glucose utilization is increased, sensitivity to insulin is increased, or insulin clearance is decreased (Table 8). However, although each of these needs to be considered carefully, they explain only a minority of episodes of hypoglycemia (168).

Risk factors indicative of HAAF (Table 8) follow directly from the pathophysiology discussed earlier. They include the following: 1) the degree of absolute endogenous insulin deficiency (119, 132, 169–172) that determines the extent to which insulin levels will not decrease and glucagon levels will not increase as plasma glucose levels fall in response to therapeutic hyperinsulinemia; 2) a history of severe hypoglycemia, hypoglycemia unawareness, or both (132, 169, 171), which indicates or implies recent antecedent hypoglycemia that causes an attenuated sympathoadrenal response to subsequent hypoglycemia, the key feature of HAAF. In addition, prior exercise (12, 16, 173) and sleep (12, 16, 174–176) cause HAAF. Long duration of diabetes (110) and classical diabetic autonomic neuropathy (107, 108) are associated with more severe HAAF; 3) aggressive glycemic therapy *per se* as evidenced by lower HbA_{1c} levels, lower glycemic goals, or both (117, 132, 133, 148, 169, 171, 172). As documented in controlled clinical trials (see Refs. 123 and 144), if all other factors are the same, patients treated to lower HbA_{1c} levels are at higher risk for hypoglycemia. That does not, of course, mean that one cannot both improve glycemic control and minimize the risk of hypoglycemia in individual patients (12, 84, 85, 86) as discussed earlier. Greater

glycemic variation is also associated with an increased risk of hypoglycemia (179).

Parenthetically, whereas there is evidence that glycemic control improves pregnancy outcomes in women with T1DM, this approach is associated with a substantially increased risk of hypoglycemia (180–183). Indeed, the risk factors for HAAF—previous severe hypoglycemia and lower HbA_{1c} levels (180) and previous severe hypoglycemia and impaired awareness of hypoglycemia (182)—are associated with higher rates of severe hypoglycemia in pregnant women with T1DM. Intensive insulin therapy in critically ill patients with or without diabetes also increases the frequency of hypoglycemia (184–186).

When treatment-induced hypoglycemia is a problem, each of the conventional risk factors for hypoglycemia (Table 8) should be considered carefully, and the therapeutic regimen should be adjusted appropriately. Among the sulfonylureas, hypoglycemia is less frequent with glimepiride than with glyburide (glibenclamide) (165, 166). In patients treated with insulin, changes could include switching from a twice daily NPH and regular or premixed insulin regimen to a basal-bolus insulin regimen. With respect to the latter, use of a long-acting insulin analog as the basal insulin results in less hypoglycemia than NPH insulin (159–161). With a basal-bolus insulin regimen, nocturnal or early morning hypoglycemia implicates the basal insulin whereas daytime hypoglycemia also implicates the prandial insulin. Among the latter, rapid-acting insulin analogs cause less nocturnal hypoglycemia (159). Although an insulin regimen should be tailored to the patient's lifestyle, missed meals do not obviate the need for self-monitoring of blood glucose; that is particularly important at bedtime and, when nocturnal hypoglycemia is a known or suspected problem, during the night. In that instance, continuous glucose monitoring can be helpful. In insulin-treated patients, hypoglycemia often occurs during, or shortly after, exercise (173). Planned exercise should be preceded by carbohydrate ingestion, reduced insulin doses, or both. Unplanned exercise requires careful self-monitoring of blood glucose at a minimum; that will often prompt carbohydrate ingestion. Patients who consume

alcohol need to know that alcohol can lower their plasma glucose concentrations. The effects of changes in sensitivity to insulin and of renal failure also need to be considered by the caregiver.

In addition, the risk factors indicative of HAAF in diabetes (Table 8) should be considered. Unless the cause is easily remediable, a history of severe hypoglycemia should prompt consideration of a fundamental adjustment of the regimen. Without that, the risk of a subsequent episode of severe hypoglycemia is high (132). That change could involve use of a different secretagogue or a different insulin regimen as noted earlier, a reduction of secretagogue or insulin doses, and acceptance of higher glycemic goals at least in the short term. Given a history of hypoglycemia unawareness, a 2- to 3-wk period of scrupulous avoidance of hypoglycemia is advisable because that can be expected to restore awareness (102–105). Many patients are prepared to reframe their glycemic goals, particularly once they understand that: 1) the aim is to avoid episodes of hypoglycemia rather than worsening glycemic control and 2) the strategy is designed to last weeks rather than months. However, a minority of those with unawareness have developed major psychological barriers that prevent them from cooperating with such an approach. These individuals, who may have a morbid fear of complications, often take frequent additional insulin to try and prevent their glucose levels from rising above normal. Ultimately, such behavior can prevent a successful outcome, and unawareness continues accompanied by frequent severe hypoglycemia. Finally, a history of late postexercise hypoglycemia, nocturnal hypoglycemia, or both should prompt appropriately timed regimen adjustments (generically less insulin, more carbohydrate ingestion, or both) or, failing these, a pharmacological bedtime treatment (187).

Recommendation

3.7. We recommend that urgent treatment of hypoglycemia should be accomplished by ingestion of carbohydrates, if that is feasible, or by parenteral glucagon or glucose if it is not feasible (1 | ⊕⊕⊕⊕).

3.7. Evidence

Hypoglycemia causes functional brain failure that is corrected after the plasma glucose concentration is raised in the vast majority of instances (6). Profound, prolonged hypoglycemia can cause brain death (6). Clearly, the plasma glucose concentration should be raised to normal levels promptly. Data from a rodent model of extreme hypoglycemia suggest that post-hypoglycemic glucose reperfusion contributes to neuronal death (188). The clinical extrapolation of that finding is unclear, but it may be that posttreatment hyperglycemia should be avoided, at least after an episode of profound, prolonged hypoglycemia (6).

In people with diabetes, most episodes of asymptomatic (detected by self-monitoring of blood glucose or continuous glucose sensing) or mild-to-moderate symptomatic hypoglycemia are effectively self-treated by ingestion of glucose tablets or carbohydrate-containing juice, soft drinks, milk, candy, other snacks, or a meal (12, 189). A commonly recommended dose of glucose in adults is 20 g (177). Clinical improvement should occur in 15–20 min. However, the glycemic response to oral glucose is often transient, usually less than 2 h in insulin-induced hypoglycemia (177). Therefore, ingestion of a more substantial snack or a meal shortly after the plasma glucose is raised is generally advisable. (Thus, our recommendation is based on high-quality evidence because of the large treatment effect, as compared with no treatment, associated with carbohydrate intake; compared with alternative doses of carbohydrate or other foods or treatments, the quality of the evidence is very low.) The effects of these commonly used oral treatments of hypoglycemia have not been investigated systematically in the context of contemporary diabetes treatment. Thus, the dose-response relationship between the source of ingested carbohydrate and the plasma glucose level and the time course of response cannot be stated with confidence. This would be a useful subject for investigation. Patients should be advised to monitor their blood glucose levels serially after self-treating an episode of hypoglycemia to ascertain their individual response to the carbohydrate ingested.

Parenteral treatment is necessary when a hypoglycemic patient is unwilling (because of neuroglycopenia) or unable to take carbohydrate orally. Glucagon, injected sc or im in a dose of 1.0 mg in adults by an associate of the patient, is often used. That can be lifesaving, but it often causes substantial, albeit transient, hyperglycemia (177), and it can cause nausea and even vomiting. Although glucagon can be administered iv by medical personnel, in that setting the standard parenteral therapy is iv glucose. A standard initial glucose dose is 25 g. The glycemic response to iv glucose is, of course, transient. A subsequent glucose infusion is often needed, and food should be provided orally as soon as the patient is able to ingest it safely. The duration of a hypoglycemic episode is a function of its cause. A sulfonylurea overdose can result in prolonged hypoglycemia. Hospitalization for prolonged treatment and observation may be necessary. Octreotide has been used to treat sulfonylurea-induced hypoglycemia (178).

References

1. **Atkins D, Best D, Briss PA, Eccles M, Falck-Ytter Y, Flottorp S, Guyatt GH, Harbour RT, Haugh MC, Henry D, Hill S, Jaeschke R, Leng G, Liberati A, Magrini N, Mason J, Middleton P, Mrukowicz J, O'Connell D, Oxman AD, Phillips B, Schunemann HJ, Edejer TT, Varonen H, Vist GE, Williams Jr JW, Zaza S** 2004 Grading quality of evidence and strength of recommendations. *BMJ* 328:1490
2. **Swiglo BA, Murad MH, Schunemann HJ, Kunz R, Vigersky RA, Guyatt GH, Montori VM** 2008 A case for clarity, consistency, and helpfulness: state-of-the-art clinical practice guidelines in endocrinology using the grading of recommendations, assessment, development, and evaluation system. *J Clin Endocrinol Metab* 93:666–673
3. **Whipple AO** 1938 The surgical therapy of hyperinsulinism. *J Int Chir* 3:237–276
4. **Towler DA, Havlin CE, Craft S, Cryer P** 1993 Mechanism of awareness of hypoglycemia. Perception of neurogenic (predominantly cholinergic) rather than neuroglycopenic symptoms. *Diabetes* 42:1791–1798
5. **DeRosa MA, Cryer PE** 2004 Hypoglycemia and the sympathoadrenal system: neurogenic symptoms are largely the result of sympathetic neural, rather than adrenomedullary, activation. *Am J Physiol Endocrinol Metab* 287:E32–E41
6. **Cryer PE** 2007 Hypoglycemia, functional brain failure, and brain death. *J Clin Invest* 117:868–870
7. **Cryer P** 2001 The prevention and correction of hypoglycemia. In: Jefferson L, Cherrington A, Goodman H, eds. *Handbook of physiology; Section 7, the endocrine system. Volume II. The endocrine pancreas and regulation of metabolism.* New York: Oxford University Press; 1057–1092
8. **Amiel SA, Sherwin RS, Simonson DC, Tamborlane WV** 1988 Effect of intensive insulin therapy on glycemic thresholds for counterregulatory hormone release. *Diabetes* 37:901–907
9. **Boyle PJ, Schwartz NS, Shah SD, Clutter WE, Cryer PE** 1988 Plasma glucose concentrations at the onset of hypoglycemic symptoms in patients with poorly controlled diabetes and in nondiabetics. *N Engl J Med* 318:1487–1492
10. **Mitrakou A, Fanelli C, Veneman T, Perriello G, Calderone S, Platanisotis D, Rambotti A, Raptis S, Brunetti P, Cryer P, Gerich J, Bolli G** 1993 Reversibility of unawareness of hypoglycemia in patients with insulinomas. *N Engl J Med* 329:834–839
11. **Jackson RA, Peters N, Advani U, Perry G, Rogers J, Brough WH, Pilkington TR** 1973 Forearm glucose uptake during the oral glucose tolerance test in normal subjects. *Diabetes* 22:442–458
12. **Cryer P** 2008 Glucose homeostasis and hypoglycemia. In: Kronenberg H, Melmed S, Polonsky K, Larsen P, eds. *Williams textbook of endocrinology, 11th ed.* Philadelphia: Saunders, an imprint of Elsevier, Inc.; 1503–1533
13. **Guettier JM, Gorden P** 2006 Hypoglycemia. *Endocrinol Metab Clin North Am* 35:753–766
14. **Service FJ** 1995 Hypoglycemic disorders. *N Engl J Med* 332:1144–1152
15. **Service FJ** 1999 Classification of hypoglycemic disorders. *Endocrinol Metab Clin North Am* 28:501–517
16. **Cryer PE** 2004 Diverse causes of hypoglycemia-associated autonomic failure in diabetes. *N Engl J Med* 350:2272–2279
17. **Heller SR, Cryer PE** 1991 Hypoinsulinemia is not critical to glucose recovery from hypoglycemia in humans. *Am J Physiol* 261:E41–E48
18. **Fischer KE, Lees JA, Newman JH** 1986 Hypoglycemia in hospitalized patients. Causes and outcomes. *N Engl J Med* 315:1245–1250
19. **Malouf R, Brust JC** 1985 Hypoglycemia: causes, neurological manifestations, and outcome. *Ann Neurol* 17:421–430
20. **Marks V, Teale JD** 1999 Drug-induced hypoglycemia. *Endocrinol Metab Clin North Am* 28:555–577
21. **Park-Wyllie LY, Juurlink DN, Kopp A, Shah BR, Stukel TA, Stumpo C, Dresser L, Low DE, Mamdani MM** 2006 Outpatient gatifloxacin therapy and dysglycemia in older adults. *N Engl J Med* 354:1352–1361
22. **Marks V, Teale JD** 1999 Hypoglycemia: factitious and felonious. *Endocrinol Metab Clin North Am* 28:579–601
23. **Service FJ** 1987 Endocrine causes of postprandial hypoglycemia. In: Andreani D, Marks V, Lefebvre PJ, eds. *Serono Symposia.* New York: Raven Press; 45–54
24. **Murad MH, Coto Yglesias F, Wang AT, Mullan RJ, Elamin M, Sheidaee N, Erwin PJ, Montori VM** Drug-induced hypoglycemia: a systematic review. *J Clin Endocrinol Metab* 94:741–745
25. **Cohen MR, Proulx SM, Crawford SY** 1998 Survey of hospital systems and common serious medication errors. *J Healthc Risk Manag* 18:16–27
26. **Clement S, Braithwaite SS, Magee ME, Ahmann A, Smith EP, Schafer RG, Hirsch IB** 2004 Management of diabetes and hyperglycemia in hospitals. *Diabetes Care* 27:553–591
27. **Fukuda I, Hizuka N, Ishikawa Y, Yasumoto K, Murakami Y, Sata A, Morita J, Kurimoto M, Okubo Y, Takano K** 2006 Clinical features of insulin-like growth factor-II producing non-islet-cell tumor hypoglycemia. *Growth Horm IGF Res* 16:211–216

28. Nauck MA, Reinecke M, Perren A, Frystyk J, Berishvili G, Zwimpfer C, Figge AM, Flyvbjerg A, Lankisch PG, Blum WF, Kloppel G, Schmiegel W, Zapf J 2007 Hypoglycemia due to paraneoplastic secretion of insulin-like growth factor-I in a patient with metastasizing large-cell carcinoma of the lung. *J Clin Endocrinol Metab* 92:1600–1605
29. Miraki-Moud F, Grossman AB, Besser M, Monson JP, Camacho-Hubner C 2005 A rapid method for analyzing serum pro-insulin-like growth factor-II in patients with non-islet cell tumor hypoglycemia. *J Clin Endocrinol Metab* 90:3819–3823
30. Daughaday WH 2007 Hypoglycemia due to paraneoplastic secretion of insulin-like growth factor-I. *J Clin Endocrinol Metab* 92:1616
31. Bates DW 2002 Unexpected hypoglycemia in a critically ill patient. *Ann Intern Med* 137:110–116
32. Grunberger G, Weiner JL, Silverman R, Taylor S, Gorden P 1988 Factitious hypoglycemia due to surreptitious administration of insulin. Diagnosis, treatment, and long-term follow-up. *Ann Intern Med* 108:252–257
33. Jordan RM, Kammer H, Riddle MR 1977 Sulfonylurea-induced factitious hypoglycemia. A growing problem. *Arch Intern Med* 137:390–393
34. Scarlett JA, Mako ME, Rubenstein AH, Blix PM, Goldman J, Horwitz DL, Tager H, Jaspan JB, Stjernholm MR, Olefsky JM 1977 Factitious hypoglycemia. Diagnosis by measurement of serum C-peptide immunoreactivity and insulin-binding antibodies. *N Engl J Med* 297:1029–1032
35. Service FJ, Palumbo PJ 1974 Factitial hypoglycemia. Three cases diagnosed on the basis of insulin antibodies. *Arch Intern Med* 134:336–340
36. Giurgea I, Ulinski T, Touati G, Sempoux C, Mochel F, Brunelle F, Saudubray JM, Fekete C, de Lonlay P 2005 Factitious hyperinsulinism leading to pancreatotomy: severe forms of Munchausen syndrome by proxy. *Pediatrics* 116:e145–e148
37. Manning PJ, Espiner EA, Yoon K, Drury PL, Holdaway IM, Bowers A 2003 An unusual cause of hyperinsulinaemic hypoglycaemia syndrome. *Diabet Med* 20:772–776
38. Kar P, Price P, Sawers S, Bhattacharya S, Reznik RH, Grossman AB 2006 Insulinomas may present with normoglycemia after prolonged fasting but glucose-stimulated hypoglycemia. *J Clin Endocrinol Metab* 91:4733–4736
39. Power L 1969 A glucose-responsive insulinoma. *JAMA* 207:893–896
40. Service FJ, McMahon MM, O'Brien PC, Ballard DJ 1991 Functioning insulinoma—incidence, recurrence, and long-term survival of patients: a 60-year study. *Mayo Clin Proc* 66:711–719
41. Service FJ 2006 Recurrent hyperinsulinemic hypoglycemia caused by an insulin-secreting insulinoma. *Nat Clin Pract Endocrinol Metab* 2:467–470
42. Service FJ, Natt N, Thompson GB, Grant CS, van Heerden JA, Andrews JC, Lorenz E, Terzic A, Lloyd RV 1999 Noninsulinoma pancreatogenous hypoglycemia: a novel syndrome of hyperinsulinemic hypoglycemia in adults independent of mutations in Kir6.2 and SUR1 genes. *J Clin Endocrinol Metab* 84:1582–1589
43. Starke A, Saddig C, Kirch B, Tschahargane C, Goretzki P 2006 Islet hyperplasia in adults: challenge to preoperatively diagnose non-insulinoma pancreatogenic hypoglycemia syndrome. *World J Surg* 30:670–679
44. Thompson GB, Service FJ, Andrews JC, Lloyd RV, Natt N, van Heerden JA, Grant CS 2000 Noninsulinoma pancreatogenous hypoglycemia syndrome: an update in 10 surgically treated patients. *Surgery* 128:937–944; discussion, 944–945
45. Won JG, Tseng HS, Yang AH, Tang KT, Jap TS, Lee CH, Lin HD, Burcus N, Pittenger G, Vinik A 2006 Clinical features and morphological characterization of 10 patients with noninsulinoma pancreatogenous hypoglycaemia syndrome (NIPHS). *Clin Endocrinol (Oxf)* 65:566–578
46. Anlauf M, Wieben D, Perren A, Sipos B, Komminoth P, Raffel A, Kruse ML, Fottner C, Knoefel WT, Monig H, Heitz PU, Kloppel G 2005 Persistent hyperinsulinemic hypoglycemia in 15 adults with diffuse nesidioblastosis: diagnostic criteria, incidence, and characterization of β -cell changes. *Am J Surg Pathol* 29:524–533
47. Kloppel G, Anlauf M, Raffel A, Perren A, Knoefel WT 2008 Adult diffuse nesidioblastosis: genetically or environmentally induced? *Hum Pathol* 39:3–8
48. Service GJ, Thompson GB, Service FJ, Andrews JC, Collazo-Clavell ML, Lloyd RV 2005 Hyperinsulinemic hypoglycemia with nesidioblastosis after gastric-bypass surgery. *N Engl J Med* 353:249–254
49. Patti ME, McMahon G, Mun EC, Bitton A, Holst JJ, Goldsmith J, Hanto DW, Callery M, Arky R, Nose V, Bonner-Weir S, Goldfine AB 2005 Severe hypoglycaemia post-gastric bypass requiring partial pancreatectomy: evidence for inappropriate insulin secretion and pancreatic islet hyperplasia. *Diabetologia* 48:2236–2240
50. Goldfine AB, Mun E, Patti ME 2006 Hyperinsulinemic hypoglycemia following gastric bypass surgery for obesity. *Curr Opin Endocrinol Diabetes* 13:419–424
51. Vella A, Thompson GB, Grant CS, Andrews JC, Lloyd RV, Service FJ, Postprandial hypoglycemia after upper gastrointestinal surgery. Program and Abstracts, The Endocrine Society's 89th Annual Meeting, p. 697 (Abstract P4–P121)
52. Goldfine AB, Mun EC, Devine E, Bernier R, Baz-Hecht M, Jones DB, Schneider BE, Holst JJ, Patti ME 2007 Patients with neuroglycopenia after gastric bypass surgery have exaggerated incretin and insulin secretory responses to a mixed meal. *J Clin Endocrinol Metab* 92:4678–4685
53. Meier JJ, Butler AE, Galasso R, Butler PC 2006 Hyperinsulinemic hypoglycemia after gastric bypass surgery is not accompanied by islet hyperplasia or increased β -cell turnover. *Diabetes Care* 29:1554–1559

54. Vella A, Service FJ 2007 Incretin hypersecretion in post-gastric bypass hypoglycemia—primary problem or red herring? *J Clin Endocrinol Metab* 92:4563–4565
55. Hirata Y, Ishizu H, Ouchi N, Motomura S, Abe M, Hara Y, Wakasugi H, Takahashi I, Sakani H, Tanaka M, Kawano H, Kanesaka T 1970 Insulin autoimmunity in a case with spontaneous hypoglycemia. *J Japan Diab Soc* 13:312–320
56. Basu A, Service FJ, Yu L, Hesser D, Ferries LM, Eisenbarth G 2005 Insulin autoimmunity and hypoglycemia in seven white patients. *Endocr Pract* 11:97–103
57. Halsall DJ, Mangi M, Soos M, Fahie-Wilson MN, Wark G, Mainwaring-Burton R, O’Rahilly S 2007 Hypoglycemia due to an insulin binding antibody in a patient with an IgA- κ myeloma. *J Clin Endocrinol Metab* 92:2013–2016
58. Rizza RA, Haymond MW, Verdonk CA, Mandarino LJ, Miles JM, Service FJ, Gerich JE 1981 Pathogenesis of hypoglycemia in insulinoma patients: suppression of hepatic glucose production by insulin. *Diabetes* 30:377–381
59. Service FJ, Dale AJ, Elveback LR, Jiang NS 1976 Insulinoma: clinical and diagnostic features of 60 consecutive cases. *Mayo Clin Proc* 51:417–429
60. Service FJ, Natt N 2000 The prolonged fast. *J Clin Endocrinol Metab* 85:3973–3974
61. Vezzosi D, Bennet A, Fauvel J, Caron P 2007 Insulin, C-peptide and proinsulin for the biochemical diagnosis of hypoglycaemia related to endogenous hyperinsulinism. *Eur J Endocrinol* 157:75–83
62. Service FJ, O’Brien PC 2005 Increasing serum β -hydroxybutyrate concentrations during the 72-hour fast: evidence against hyperinsulinemic hypoglycemia. *J Clin Endocrinol Metab* 90:4555–4558
63. Hogan MJ, Service FJ, Sharbrough FW, Gerich JE 1983 Oral glucose tolerance test compared with a mixed meal in the diagnosis of reactive hypoglycemia. A caveat on stimulation. *Mayo Clin Proc* 58:491–496
64. Kaczirek K, Soleiman A, Schindl M, Passler C, Scheuba C, Prager G, Kaserer K, Niederle B 2003 Nesidioblastosis in adults: a challenging cause of organic hyperinsulinism. *Eur J Clin Invest* 33:488–492
65. Witteles RM, Straus IF, Sugg SL, Koka MR, Costa EA, Kaplan EL 2001 Adult-onset nesidioblastosis causing hypoglycemia: an important clinical entity and continuing treatment dilemma. *Arch Surg* 136:656–663
66. Rayman G, Santo M, Salomon F, Almog S, Paradinas FJ, Pinkhas J, Reynolds KW, Wise PH 1984 Hyperinsulinaemic hypoglycaemia due to chlorpropamide-induced nesidioblastosis. *J Clin Pathol* 37:651–654
67. Seckl MJ, Mulholland PJ, Bishop AE, Teale JD, Hales CN, Glaser M, Watkins S, Seckl JR 1999 Hypoglycemia due to an insulin-secreting small-cell carcinoma of the cervix. *N Engl J Med* 341:733–736
68. Hojlund K, Hansen T, Lajer M, Henriksen JE, Levin K, Lindholm J, Pedersen O, Beck-Nielsen H 2004 A novel syndrome of autosomal-dominant hyperinsulinemic hypoglycemia linked to a mutation in the human insulin receptor gene. *Diabetes* 53:1592–1598
69. Meissner T, Friedmann B, Okun JG, Schwab MA, Otonkoski T, Bauer T, Bartsch P, Mayatepek E 2005 Massive insulin secretion in response to anaerobic exercise in exercise-induced hyperinsulinism. *Horm Metab Res* 37:690–694
70. Arioglu E, Andewelt A, Diabo C, Bell M, Taylor SI, Gorden P 2002 Clinical course of the syndrome of autoantibodies to the insulin receptor (type B insulin resistance): a 28-year perspective. *Medicine (Baltimore)* 81:87–100
71. Grossman AB, Reznick RH 2005 Commentary: imaging of islet-cell tumours. *Best Pract Res Clin Endocrinol Metab* 19:241–243
72. Kaltsas GA, Besser GM, Grossman AB 2004 The diagnosis and medical management of advanced neuroendocrine tumors. *Endocr Rev* 25:458–511
73. Noone TC, Hosey J, Firat Z, Semelka RC 2005 Imaging and localization of islet-cell tumours of the pancreas on CT and MRI. *Best Pract Res Clin Endocrinol Metab* 19:195–211
74. Virgolini I, Traub-Weidinger T, Decristoforo C 2005 Nuclear medicine in the detection and management of pancreatic islet-cell tumours. *Best Pract Res Clin Endocrinol Metab* 19:213–227
75. Kumbasar B, Kamel IR, Tekes A, Eng J, Fishman EK, Wahl RL 2004 Imaging of neuroendocrine tumors: accuracy of helical CT versus SRS. *Abdom Imaging* 29:696–702
76. Fritscher-Ravens A 2004 Endoscopic ultrasound and neuroendocrine tumours of the pancreas. *JOP* 5:273–281
77. McLean AM, Fairclough PD 2005 Endoscopic ultrasound in the localisation of pancreatic islet cell tumours. *Best Pract Res Clin Endocrinol Metab* 19:177–193
78. Nikfarjam M, Warshaw AL, Axelrod L, Deshpande V, Thayer SP, Ferrone CR, Fernandez-del Castillo C 2008 Improved contemporary surgical management of insulinomas: a 25-year experience at the Massachusetts General Hospital. *Ann Surg* 247:165–172
79. Brown CK, Bartlett DL, Doppman JL, Gorden P, Libutti SK, Fraker DL, Shawker TH, Skarulis MC, Alexander HR 1997 Intraarterial calcium stimulation and intraoperative ultrasonography in the localization and resection of insulinomas. *Surgery* 122:1189–1193
80. Doppman JL, Miller DL, Chang R, Shawker TH, Gorden P, Norton JA 1991 Insulinomas: localization with selective intraarterial injection of calcium. *Radiology* 178:237–241
81. Wiesli P, Brande M, Schmid C, Krahenbuhl L, Furrer J, Keller U, Spinaz GA, Pfammatter T 2004 Selective arterial calcium stimulation and hepatic venous sampling in the evaluation of hyperinsulinemic hypoglycemia: potential and limitations. *J Vasc Interv Radiol* 15:1251–1256

82. **Jackson JE** 2005 Angiography and arterial stimulation venous sampling in the localization of pancreatic neuroendocrine tumours. *Best Pract Res Clin Endocrinol Metab* 19:229–239
83. **Kauhanen S, Seppanen M, Minn H, Gullichsen R, Salonen A, Alanen K, Parkkola R, Solin O, Bergman J, Sane T, Salmi J, Valimaki M, Nuutila P** 2007 Fluorine-18-L-dihydroxyphenylalanine (18F-DOPA) positron emission tomography as a tool to localize an insulinoma or β -cell hyperplasia in adult patients. *J Clin Endocrinol Metab* 92:1237–1244
84. **Cryer PE** 2002 Hypoglycaemia: the limiting factor in the glycaemic management of type I and type II diabetes. *Diabetologia* 45:937–948
85. **Cryer PE, Davis SN, Shamooh H** 2003 Hypoglycemia in diabetes. *Diabetes Care* 26:1902–1912
86. **Rossetti P, Porcellati F, Bolli GB, Fanelli CG** 2008 Prevention of hypoglycemia while achieving good glycaemic control in type 1 diabetes: the role of insulin analogs. *Diabetes Care* 31(Suppl 2):S113–S120
87. 1995 UK Prospective Diabetes Study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. UK Prospective Diabetes Study Group. *Diabetes* 44:1249–1258
88. **de Heer J, Holst JJ** 2007 Sulfonylurea compounds uncouple the glucose dependence of the insulinotropic effect of glucagon-like peptide 1. *Diabetes* 56:438–443
89. **Dagogo-Jack SE, Craft S, Cryer PE** 1993 Hypoglycemia-associated autonomic failure in insulin-dependent diabetes mellitus. Recent antecedent hypoglycemia reduces autonomic responses to, symptoms of, and defense against subsequent hypoglycemia. *J Clin Invest* 91:819–828
90. **Segel SA, Paramore DS, Cryer PE** 2002 Hypoglycemia-associated autonomic failure in advanced type 2 diabetes. *Diabetes* 51:724–733
91. **Raju B, Cryer PE** 2005 Loss of the decrement in in-traitlet insulin plausibly explains loss of the glucagon response to hypoglycemia in insulin-deficient diabetes: documentation of the in-traitlet insulin hypothesis in humans. *Diabetes* 54:757–764
92. **Gerich JE, Langlois M, Noacco C, Karam JH, Forsham PH** 1973 Lack of glucagon response to hypoglycemia in diabetes: evidence for an intrinsic pancreatic α gr; cell defect. *Science* 182:171–173
93. **Boden G, Reichard Jr GA, Hoeldtke RD, Rezvani I, Owen OE** 1981 Severe insulin-induced hypoglycemia associated with deficiencies in the release of counterregulatory hormones. *N Engl J Med* 305:1200–1205
94. **Bolli G, de Feo P, Compagnucci P, Cartechini MG, Angeletti G, Santeusano F, Brunetti P, Gerich JE** 1983 Abnormal glucose counterregulation in insulin-dependent diabetes mellitus. Interaction of anti-insulin antibodies and impaired glucagon and epinephrine secretion. *Diabetes* 32:134–141
95. **Cryer PE** 2006 Mechanisms of sympathoadrenal failure and hypoglycemia in diabetes. *J Clin Invest* 116:1470–1473
96. **Cryer PE** 2005 Mechanisms of hypoglycemia-associated autonomic failure and its component syndromes in diabetes. *Diabetes* 54:3592–3601
97. **Heller SR, Cryer PE** 1991 Reduced neuroendocrine and symptomatic responses to subsequent hypoglycemia after 1 episode of hypoglycemia in nondiabetic humans. *Diabetes* 40:223–226
98. **White NH, Skor DA, Cryer PE, Levandoski LA, Bier DM, Santiago JV** 1983 Identification of type I diabetic patients at increased risk for hypoglycemia during intensive therapy. *N Engl J Med* 308:485–491
99. **Bolli GB, De Feo P, De Cosmo S, Perriello G, Ventura MM, Benedetti MM, Santeusano F, Gerich JE, Brunetti P** 1984 A reliable and reproducible test for adequate glucose counterregulation in type I diabetes mellitus. *Diabetes* 33:732–737
100. **Gold AE, MacLeod KM, Frier BM** 1994 Frequency of severe hypoglycemia in patients with type I diabetes with impaired awareness of hypoglycemia. *Diabetes Care* 17:697–703
101. **Davis MR, Mellman M, Shamooh H** 1992 Further defects in counterregulatory responses induced by recurrent hypoglycemia in IDDM. *Diabetes* 41:1335–1340
102. **Fanelli CG, Epifano L, Rambotti AM, Pampanelli S, Di Vincenzo A, Modarelli F, Lepore M, Annibale B, Ciofetta M, Bottini P, Porcellati F, Scionti L, Santeusano F, Brunetti P, Bolli GB** 1993 Meticulous prevention of hypoglycemia normalizes the glycaemic thresholds and magnitude of most of neuroendocrine responses to, symptoms of, and cognitive function during hypoglycemia in intensively treated patients with short-term IDDM. *Diabetes* 42:1683–1689
103. **Fanelli C, Pampanelli S, Epifano L, Rambotti AM, Di Vincenzo A, Modarelli F, Ciofetta M, Lepore M, Annibale B, Torlone E, Perriello G, De Feo P, Santeusano F, Brunetti P, Bolli GB** 1994 Long-term recovery from unawareness, deficient counterregulation and lack of cognitive dysfunction during hypoglycaemia, following institution of rational, intensive insulin therapy in IDDM. *Diabetologia* 37:1265–1276
104. **Cranston I, Lomas J, Maran A, Macdonald I, Amiel SA** 1994 Restoration of hypoglycaemia awareness in patients with long-duration insulin-dependent diabetes. *Lancet* 344:283–287
105. **Dagogo-Jack S, Rattarasarn C, Cryer PE** 1994 Reversal of hypoglycemia unawareness, but not defective glucose counterregulation, in IDDM. *Diabetes* 43:1426–1434
106. **Rickels MR, Schutta MH, Mueller R, Kapoor S, Markmann JE, Naji A, Teff KL** 2007 Glycaemic thresholds for activation of counterregulatory hormone and symptom responses in islet transplant recipients. *J Clin Endocrinol Metab* 92:873–879
107. **Bottini P, Boschetti E, Pampanelli S, Ciofetta M, Del Sindaco P, Scionti L, Brunetti P, Bolli GB** 1997 Contribution of autonomic neuropathy to reduced plasma adrenaline responses to hypoglycemia in IDDM: evidence for a nonselective defect. *Diabetes* 46:814–823

108. Meyer C, Grossmann R, Mitrakou A, Mahler R, Veneman T, Gerich J, Bretzel RG 1998 Effects of autonomic neuropathy on counterregulation and awareness of hypoglycemia in type 1 diabetic patients. *Diabetes Care* 21:1960–1966
109. De Galan BE, Tack CJ, Willemsen JJ, Sweep CG, Smits P, Lenders JW 2004 Plasma metanephrine levels are decreased in type 1 diabetic patients with a severely impaired epinephrine response to hypoglycemia, indicating reduced adrenomedullary stores of epinephrine. *J Clin Endocrinol Metab* 89:2057–2061
110. Pedersen-Bjergaard U, Pramming S, Heller SR, Wallace TM, Rasmussen AK, Jorgensen HV, Matthews DR, Hougaard P, Thorsteinsson B 2004 Severe hypoglycaemia in 1076 adult patients with type 1 diabetes: influence of risk markers and selection. *Diabetes Metab Res Rev* 20:479–486
111. Laing SP, Swerdlow AJ, Slater SD, Botha JL, Burden AC, Waugh NR, Smith AW, Hill RD, Bingley PJ, Patterson CC, Qiao Z, Keen H 1999 The British Diabetic Association Cohort Study, II: cause-specific mortality in patients with insulin-treated diabetes mellitus. *Diabet Med* 16:466–471
112. Lee SP, Yeoh L, Harris ND, Davies CM, Robinson RT, Leathard A, Newman C, Macdonald IA, Heller SR 2004 Influence of autonomic neuropathy on QTc interval lengthening during hypoglycemia in type 1 diabetes. *Diabetes* 53:1535–1542
113. Robinson RT, Harris ND, Ireland RH, Lee S, Newman C, Heller SR 2003 Mechanisms of abnormal cardiac repolarization during insulin-induced hypoglycemia. *Diabetes* 52:1469–1474
114. Gill G, Woodward A, Casson I, Weston P 2007 Exploring the 'dead in bed syndrome': a real life study of nocturnal hypoglycaemia, QT interval prolongation and cardiac arrhythmia. *Diabet Med* 24 (Suppl 1):13 (Abstract)
115. Murphy NP, Ford-Adams ME, Ong KK, Harris ND, Keane SM, Davies C, Ireland RH, MacDonald IA, Knight EJ, Edge JA, Heller SR, Dunger DB 2004 Prolonged cardiac repolarisation during spontaneous nocturnal hypoglycaemia in children and adolescents with type 1 diabetes. *Diabetologia* 47:1940–1947
116. Tattersall RB, Gill GV 1991 Unexplained deaths of type 1 diabetic patients. *Diabet Med* 8:49–58
117. Gerstein HC, Miller ME, Byington RP, Goff Jr DC, Bigger JT, Buse JB, Cushman WC, Genuth S, Ismail-Beigi F, Grimm Jr RH, Probstfield JL, Simons-Morton DG, Friedewald WT 2008 Effects of intensive glucose lowering in type 2 diabetes. The Action to Control Cardiovascular Risk in Diabetes Study Group. *N Engl J Med* 358:2545–2559
118. 1998 United Kingdom Prospective Diabetes Study 24: a 6-year, randomized, controlled trial comparing sulfonylurea, insulin, and metformin therapy in patients with newly diagnosed type 2 diabetes that could not be controlled with diet therapy. United Kingdom Prospective Diabetes Study Group. *Ann Intern Med* 128:165–175
119. 2007 Risk of hypoglycaemia in types 1 and 2 diabetes: effects of treatment modalities and their duration. UK Hypoglycaemia Study Group. *Diabetologia* 50:1140–1147
120. MacLeod KM, Hepburn DA, Frier BM 1993 Frequency and morbidity of severe hypoglycaemia in insulin-treated diabetic patients. *Diabet Med* 10:238–245
121. Donnelly LA, Morris AD, Frier BM, Ellis JD, Donnan PT, Durrant R, Band MM, Reekie G, Leese GP 2005 Frequency and predictors of hypoglycaemia in type 1 and insulin-treated type 2 diabetes: a population-based study. *Diabet Med* 22:749–755
122. Reichard P, Pihl M 1994 Mortality and treatment side-effects during long-term intensified conventional insulin treatment in the Stockholm Diabetes Intervention Study. *Diabetes* 43:313–317
123. 1993 The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. *N Engl J Med* 329:977–986
124. Akram K, Pedersen-Bjergaard U, Carstensen B, Borch-Johnsen K, Thorsteinsson B 2006 Frequency and risk factors of severe hypoglycaemia in insulin-treated type 2 diabetes: a cross-sectional survey. *Diabet Med* 23:750–756
125. Henderson JN, Allen KV, Deary IJ, Frier BM 2003 Hypoglycaemia in insulin-treated type 2 diabetes: frequency, symptoms and impaired awareness. *Diabet Med* 20:1016–1021
126. Murata GH, Duckworth WC, Shah JH, Wendel CS, Mohler MJ, Hoffman RM 2005 Hypoglycemia in stable, insulin-treated veterans with type 2 diabetes: a prospective study of 1662 episodes. *J Diabetes Complications* 19:10–17
127. Saudek CD, Duckworth WC, Giobbie-Hurder A, Henderson WG, Henry RR, Kelley DE, Edelman SV, Zieve FJ, Adler RA, Anderson JW, Anderson RJ, Hamilton BP, Donner TW, Kirkman MS, Morgan NA 1996 Implantable insulin pump vs multiple-dose insulin for non-insulin-dependent diabetes mellitus: a randomized clinical trial. Department of Veterans Affairs Implantable Insulin Pump Study Group. *JAMA* 276:1322–1327
128. Gurlek A, Erbas T, Gedik O 1999 Frequency of severe hypoglycaemia in type 1 and type 2 diabetes during conventional insulin therapy. *Exp Clin Endocrinol Diabetes* 107:220–224
129. Abaira C, Colwell JA, Nuttall FQ, Sawin CT, Nagel NJ, Comstock JP, Emanuele NV, Levin SR, Henderson W, Lee HS 1995 Veterans Affairs Cooperative Study on glycemic control and complications in type II diabetes (VA CSDM). Results of the feasibility trial. Veterans Affairs Cooperative Study in Type II Diabetes. *Diabetes Care* 18:1113–1123
130. Yki-Jarvinen H, Ryysy L, Nikkila K, Tulokas T, Vanamo R, Heikkila M 1999 Comparison of bedtime insulin regimens in patients with type 2 diabetes mellitus. A randomized, controlled trial. *Ann Intern Med* 130:389–396

131. **Ohkubo Y, Kishikawa H, Araki E, Miyata T, Isami S, Motoyoshi S, Kojima Y, Furuyoshi N, Shichiri M** 1995 Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. *Diabetes Res Clin Pract* 28:103–117
132. **Wright AD, Cull CA, Macleod KM, Holman RR** 2006 Hypoglycemia in type 2 diabetic patients randomized to and maintained on monotherapy with diet, sulfonylurea, metformin, or insulin for 6 years from diagnosis: UKPDS73. *J Diabetes Complications* 20:395–401
133. 1997 Hypoglycemia in the Diabetes Control and Complications Trial. The Diabetes Control and Complications Trial Research Group. *Diabetes* 46:271–286
134. **Holstein A, Plaschke A, Egberts EH** 2003 Clinical characterisation of severe hypoglycaemia—a prospective population-based study. *Exp Clin Endocrinol Diabetes* 111:364–369
135. **Leese GP, Wang J, Broomhall J, Kelly P, Marsden A, Morrison W, Frier BM, Morris AD** 2003 Frequency of severe hypoglycemia requiring emergency treatment in type 1 and type 2 diabetes: a population-based study of health service resource use. *Diabetes Care* 26:1176–1180
136. 2005 Defining and reporting hypoglycemia in diabetes: a report from the American Diabetes Association Workgroup on Hypoglycemia. *Diabetes Care* 28:1245–1249
137. **Davis SN, Shavers C, Mosqueda-Garcia R, Costa F** 1997 Effects of differing antecedent hypoglycemia on subsequent counterregulation in normal humans. *Diabetes* 46:1328–1335
138. 2003 A multicenter study of the accuracy of the One Touch Ultra home glucose meter in children with type 1 diabetes. The Diabetes Research in Children Network (DirecNet) Study Group. *Diabetes Technol Ther* 5:933–941
139. **Buckingham B, Beck RW, Tamborlane WV, Xing D, Kollman C, Fiallo-Scharer R, Mauras N, Ruedy KJ, Tansey M, Weinzimer SA, Wysocki T** 2007 Continuous glucose monitoring in children with type 1 diabetes. *J Pediatr* 151:388–393
140. **Deiss D, Hartmann R, Schmidt J, Kordonouri O** 2006 Results of a randomised controlled cross-over trial on the effect of continuous subcutaneous glucose monitoring (CGMS) on glycaemic control in children and adolescents with type 1 diabetes. *Exp Clin Endocrinol Diabetes* 114:63–67
141. **Garg S, Zisser H, Schwartz S, Bailey T, Kaplan R, Ellis S, Jovanovic L** 2006 Improvement in glycemic excursions with a transcutaneous, real-time continuous glucose sensor: a randomized controlled trial. *Diabetes Care* 29:44–50
142. **Hovorka R** 2006 Continuous glucose monitoring and closed-loop systems. *Diabet Med* 23:1–12
143. **Steil GM, Rebrin K, Darwin C, Hariri F, Saad MF** 2006 Feasibility of automating insulin delivery for the treatment of type 1 diabetes. *Diabetes* 55:3344–3350
144. 1998 Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. *Lancet* 352:837–853
145. 1998 Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. *Lancet* 352:854–865
146. **Nathan DM, Cleary PA, Backlund JY, Genuth SM, Lachin JM, Orchard TJ, Raskin P, Zinman B** 2005 Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. *N Engl J Med* 353:2643–2653
147. **Stettler C, Allemann S, Juni P, Cull CA, Holman RR, Egger M, Krahenbuhl S, Diem P** 2006 Glycemic control and macrovascular disease in types 1 and 2 diabetes mellitus: meta-analysis of randomized trials. *Am Heart J* 152:27–38
148. **ADVANCE Collaborative Group, Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, Marre M, Cooper M, Glasziou P, Grobbee D, Hamet P, Harrap S, Heller S, Liu L, Mancia G, Mogensen CE, Pan C, Poulter N, Rodgers A, Williams B, Bompoint S, de Galan BE, Joshi R, Travert F** 2008 Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. *N Engl J Med* 358:2560–2572
149. **Qaseem A, Vijan S, Snow V, Cross JT, Weiss KB, Owens DK** 2007 Glycemic control and type 2 diabetes mellitus: the optimal hemoglobin A1c targets. A guidance statement from the American College of Physicians. *Ann Intern Med* 147:417–422
150. 2008 Standards of medical care in diabetes-2008. American Diabetes Association. *Diabetes Care* 31(Suppl 1):S12–S54
151. 1995 The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the diabetes control and complications trial. Diabetes Control and Complications Trial Research Group. *Diabetes* 44:968–983
152. **Lachin JM, Genuth S, Nathan DM, Zinman B, Rutledge BN** 2008 Effect of glycemic exposure on the risk of microvascular complications in the diabetes control and complications trial-revisited. *Diabetes* 57:995–1001
153. **Kinsley BT, Weinger K, Bajaj M, Levy CJ, Simonson DC, Quigley M, Cox DJ, Jacobson AM** 1999 Blood glucose awareness training and epinephrine responses to hypoglycemia during intensive treatment in type 1 diabetes. *Diabetes Care* 22:1022–1028
154. **Samann A, Muhlhauser I, Bender R, Kloos C, Muller UA** 2005 Glycaemic control and severe hypoglycaemia following training in flexible, intensive insulin therapy to enable dietary freedom in people with type 1 diabetes: a prospective implementation study. *Diabetologia* 48:1965–1970
155. **Buckingham B, Caswell K, Wilson DM** 2007 Real-time continuous glucose monitoring. *Curr Opin Endocrinol Diabetes Obes* 14:288–295

156. **Hirsch IB, Armstrong D, Bergenstal RM, Buckingham B, Childs BP, Clarke WL, Peters A, Wolpert H** 2008 Clinical application of emerging sensor technologies in diabetes management: consensus guidelines for continuous glucose monitoring. *Diabetes Technol Ther* 10:232–244
157. **Golicki DT, Golicka D, Groele L, Pankowska E** 2008 Continuous glucose monitoring system in children with type 1 diabetes mellitus: a systematic review and meta-analysis. *Diabetologia* 51:233–240
158. **The Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group** 2008 Continuous glucose monitoring and intensive treatment of type 1 diabetes. *N Engl J Med* 359:1464–1476
159. **Gough SC** 2007 A review of human and analogue insulin trials. *Diabetes Res Clin Pract* 77:1–15
160. **Hirsch IB** 2005 Insulin analogues. *N Engl J Med* 352:174–183
161. **Horvath K, Jentler K, Berghold A, Ebrahim SH, Gratzner TW, Plank J, Kaiser T, Pieber TR, Siebenhofer A** 2007 Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus. *Cochrane Database Syst Rev*:CD005613
162. **Riddle MC, Rosenstock J, Gerich J** 2003 The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. *Diabetes Care* 26:3080–3086
163. **Skylar JS, Ponder S, Kruger DF, Matheson D, Parkin CG** 2007 Is there a place for insulin pump therapy in your practice? *Clin Diabetes* 25:50–56
164. **Fatourechi M, Kudva Y, Murad M, Elamin M, Tabini C, Montori V** 16 December 2008 Hypoglycemia with intensive insulin therapy: a systematic review and meta-analysis of randomized trials of continuous subcutaneous insulin infusion versus multiple daily injections. *J Clin Endocrinol Metab* 94:729–740
165. **Bolen S, Feldman L, Vassy J, Wilson L, Yeh HC, Marinopoulos S, Wiley C, Selvin E, Wilson R, Bass EB, Brancati FL** 2007 Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus. *Ann Intern Med* 147:386–399
166. **Gangji AS, Cukierman T, Gerstein HC, Goldsmith CH, Clase CM** 2007 A systematic review and meta-analysis of hypoglycemia and cardiovascular events: a comparison of glyburide with other secretagogues and with insulin. *Diabetes Care* 30:389–394
167. **Warm EJ** 2007 Diabetes and the chronic care model: a review. *Curr Diabetes Rev* 3:219–225
168. 1991 Epidemiology of severe hypoglycemia in the diabetes control and complications trial. The DCCT Research Group. *Am J Med* 90:450–459
169. **Allen C, LeCaire T, Palta M, Daniels K, Meredith M, D'Alessio DJ** 2001 Risk factors for frequent and severe hypoglycemia in type 1 diabetes. *Diabetes Care* 24:1878–1881
170. **Fukuda M, Tanaka A, Tahara Y, Ikegami H, Yamamoto Y, Kumahara Y, Shima K** 1988 Correlation between minimal secretory capacity of pancreatic β -cells and stability of diabetic control. *Diabetes* 37:81–88
171. **Muhlhauser I, Overmann H, Bender R, Bott U, Berger M** 1998 Risk factors of severe hypoglycaemia in adult patients with type I diabetes—a prospective population based study. *Diabetologia* 41:1274–1282
172. **Steffes MW, Sibley S, Jackson M, Thomas W** 2003 β -Cell function and the development of diabetes-related complications in the Diabetes Control and Complications Trial. *Diabetes Care* 26:832–836
173. **Camacho RC, Galassetti P, Davis SN, Wasserman DH** 2005 Glucoregulation during and after exercise in health and insulin-dependent diabetes. *Exerc Sport Sci Rev* 33:17–23
174. **Jones TW, Porter P, Sherwin RS, Davis EA, O'Leary P, Frazer F, Byrne G, Stick S, Tamborlane WV** 1998 Decreased epinephrine responses to hypoglycemia during sleep. *N Engl J Med* 338:1657–1662
175. **Banarer S, Cryer PE** 2003 Sleep-related hypoglycemia-associated autonomic failure in type 1 diabetes: reduced awakening from sleep during hypoglycemia. *Diabetes* 52:1195–1203
176. **Schultes B, Jauch-Chara K, Gais S, Hallschmid M, Reiprich E, Kern W, Oltmanns KM, Peters A, Fehm HL, Born J** 2007 Defective awakening response to nocturnal hypoglycemia in patients with type 1 diabetes mellitus. *PLoS Med* 4:e69
177. **Wiethop BV, Cryer PE** 1993 Alanine and terbutaline in treatment of hypoglycemia in IDDM. *Diabetes Care* 16:1131–1136
178. **Boyle PJ, Justice K, Krentz AJ, Nagy RJ, Schade DS** 1993 Octreotide reverses hyperinsulinemia and prevents hypoglycemia induced by sulfonyleurea overdoses. *J Clin Endocrinol Metab* 76:752–756
179. **Kilpatrick ES, Rigby AS, Goode K, Atkin SL** 2007 Relating mean blood glucose and glucose variability to the risk of multiple episodes of hypoglycaemia in type 1 diabetes. *Diabetologia* 50:2553–2561
180. **Evers IM, ter Braak EW, de Valk HW, van Der Schoot B, Janssen N, Visser GH** 2002 Risk indicators predictive for severe hypoglycemia during the first trimester of type 1 diabetic pregnancy. *Diabetes Care* 25:554–559
181. **Mathiesen ER, Kinsley B, Amiel SA, Heller S, McCance D, Duran S, Bellaire S, Raben A** 2007 Maternal glycemic control and hypoglycemia in type 1 diabetic pregnancy: a randomized trial of insulin aspart versus human insulin in 322 pregnant women. *Diabetes Care* 30:771–776
182. **Nielsen LR, Pedersen-Bjergaard U, Thorsteinsson B, Johansen M, Damm P, Mathiesen ER** 2008 Hypoglycemia in pregnant women with type 1 diabetes: predictors and role of metabolic control. *Diabetes Care* 31:9–14

183. **ter Braak EW, Evers IM, Willem Erkelens D, Visser GH** 2002 Maternal hypoglycemia during pregnancy in type 1 diabetes: maternal and fetal consequences. *Diabetes Metab Res Rev* 18:96–105
184. **Brunkhorst FM, Engel C, Bloos F, Meier-Hellmann A, Ragaller M, Weiler N, Moerer O, Gruendling M, Opper M, Grond S, Olthoff D, Jaschinski U, John S, Rossaint R, Welte T, Schaefer M, Kern P, Kuhnt E, Kiehntopf M, Hartog C, Natanson C, Loeffler M, Reinhart K** 2008 Intensive insulin therapy and pentastarch resuscitation in severe sepsis. *N Engl J Med* 358:125–139
185. **Van den Berghe G, Wilmer A, Hermans G, Meersseman W, Wouters PJ, Milants I, Van Wijngaerden E, Bobbaers H, Bouillon R** 2006 Intensive insulin therapy in the medical ICU. *N Engl J Med* 354:449–461
186. **Van den Berghe G, Wouters P, Weekers F, Verwaest C, Bruyninckx F, Schetz M, Vlasselaers D, Ferdinande P, Lauwers P, Bouillon R** 2001 Intensive insulin therapy in the critically ill patients. *N Engl J Med* 345:1359–1367
187. **Raju B, Arbelaez AM, Breckenridge SM, Cryer PE** 2006 Nocturnal hypoglycemia in type 1 diabetes: an assessment of preventive bedtime treatments. *J Clin Endocrinol Metab* 91:2087–2092
188. **Suh SW, Gum ET, Hamby AM, Chan PH, Swanson RA** 2007 Hypoglycemic neuronal death is triggered by glucose reperfusion and activation of neuronal NADPH oxidase. *J Clin Invest* 117:910–918
189. **MacCuish AC** 1993 Treatment of hypoglycemia. In: Frier BM, Fisher BM, eds. *Diabetes and hypoglycemia*. London: Edward Arnold; 212–221

Acknowledgments

The authors gratefully acknowledge the assistance of Ms. Janet Dedeker and Dr. Patricia Stephens in the preparation of this manuscript. We thank Dr. Robert Vigersky and the Clinical Guidelines Subcommittee, the Clinical Affairs Core Committee, the Council of The Endocrine Society, the American Diabetes Association, European Association for the Study of Diabetes, and the European Society of Endocrinology for their review of this guideline. We also thank the support staff of The Endocrine Society.

Financial Disclosure of Task Force

Philip E. Cryer, M.D. (chair)—Financial or Business/Organizational Interests: consultant for the following: Amgen Inc., Johnson & Johnson, MannKind, Marcadia Biotech, Merck, Medtronic MiniMed, Novo Nordisk, Takeda, TolerRx Inc., National Institutes of Health; Significant Financial Interest or Leadership Position: past president of American Diabetes Association (1996–1997), past editor of *Diabetes* (1992–1996). **Lloyd Axelrod, M.D.**—Financial or Business/Organizational Interests: advisor or consultant for the following: American College of Physicians, American Medical Association, Best Doctors, Inc., UpToDate, Eli Lilly and Co., Smart Cells Inc., Cell Genesys Inc.; Significant Financial or Leadership Position: none declared. **Ashley B. Grossman, M.D.**—Financial or Business/Organizational Interests: consultant for the following: Novartis, Ipsen; Significant Financial or Leadership Position: none declared. **Simon R. Heller, D.M., FRCP**—Financial or Business/Organizational Interests: consultant for the following: Novo Nordisk, Aventis, Eli Lilly, MannKind, Menarini; Significant Financial Interest or Leadership Position: none declared. Consultation/Advisement: KER Unit (Mayo Clinic). ***Victor M. Montori, M.D.**—Financial or Business/Organization Interests: none declared; Consultation/Advisement: KER Unit (Mayo Clinic). **Elizabeth R. Seaquist, M.D.**—Financial or Business/Organizational Interests: Pfizer, Merck, Co., Caring for Diabetes Educational Forum; Significant Financial Interest or Leadership Position: none declared. **F. John Service, M.D., Ph.D.**—Financial or Business/Organizational Interests: American Association of Clinical Endocrinologists; Significant Financial or Leadership Position: none declared.

**Evidence based reviews for this guideline were prepared under contract with The Endocrine Society.*

THE ENDOCRINE SOCIETY GUIDELINE ORDER FORM

(Single reprint request for orders of 100 and less)

PRODUCTS	QTY.	PRICE (USD)		SUBTOTAL
		Member	Non-Member	
Androgen Therapy in Women		\$15.00	\$20.00	
Case Detection, Diagnosis & Treatment of Patients with Primary Aldosteronism		\$15.00	\$20.00	
The Diagnosis of Cushing's Syndrome		\$15.00	\$20.00	
Evaluation & Management of Adult Hypoglycemic Disorders		\$15.00	\$20.00	
Evaluation & Treatment of Adult Growth Hormone Deficiency		\$15.00	\$20.00	
Evaluation & Treatment of Hirsutism in Premenopausal Women		\$15.00	\$20.00	
Management of Thyroid Dysfunction during Pregnancy & Postpartum		Executive Summary (MMTD07)—\$10.00 Guideline (MTSD07)—\$10.00	Executive Summary (MMTD07)—\$15.00 Guideline (MTSD07)—\$15.00	
Prevention & Treatment of Pediatric Obesity		\$15.00	\$20.00	
Testosterone Therapy in Adult Men with Androgen Deficiency Syndromes		\$15.00	\$20.00	
Primary Prevention of Cardiovascular Disease & Type 2 Diabetes in Patients at Metabolic Risk		\$15.00	\$20.00	
Miscellaneous				
TOTAL		All prices include sales tax		\$

PAYMENT INFORMATION:

Check
 MasterCard
 Visa

Card Number _____ Expiration Date _____

Billing Address _____ Signature _____

Are you a member of The Endocrine Society? Yes No

If you are a member and you know your member ID, please provide: _____

Prefix:	First Name (Given):	Middle:	Last (Surname):
Institution/Company:		Dept/Div:	
Street/PO:			
City:	State/Province:	Zip/Mail Code:	Country:
Telephone:	Fax:	Email:	
Degree(s) that you would like listed after your name:		Professional Title:	Date of Birth: Gender: <input type="radio"/> Male <input type="radio"/> Female
Which of the following best describes your primary professional role? (Please mark only one)		Race or Ethnic Affiliation (voluntary)	
<input type="radio"/> Administrator <input type="radio"/> Retired <input type="radio"/> Basic Researcher <input type="radio"/> Teacher/Educator <input type="radio"/> Clinical Practitioner <input type="radio"/> Fellow (Clinical) <input type="radio"/> Clinical Researcher <input type="radio"/> Fellow (Postdoctoral/Research) <input type="radio"/> Industry/Corporate Professional <input type="radio"/> Student <input type="radio"/> Nurse/Healthcare Professional <input type="radio"/> Other _____		<input type="radio"/> African American, Black <input type="radio"/> Asian <input type="radio"/> Hispanic <input type="radio"/> Native American, Eskimo, Aleut <input type="radio"/> Pacific Islander <input type="radio"/> White, Caucasian <input type="radio"/> Other _____	

What goes into our Clinical Guidelines is a story worth telling

The extensive process that goes into creating The Endocrine Society's Clinical Guidelines not only provides validation and assurance, but also raises the standard for the development of guidelines everywhere.

The guidelines are developed using a multi-step process that reflects the standards of excellence embraced by The Endocrine Society.

Endocrine Society Clinical Guidelines Also Available:

Evaluation and Treatment of Adult Growth Hormone Deficiency

Testosterone Therapy in Adult Men with Androgen Deficiency Syndromes

*Androgen Therapy in Women
Management of Thyroid Dysfunction during Pregnancy and Postpartum*

Evaluation and Treatment of Hirsutism in Premenopausal Women

The Diagnosis of Cushing's Syndrome

Case Detection, Diagnosis, and Treatment of Patients with Primary Aldosteronism

Primary Prevention of Cardiovascular Disease and Type 2 Diabetes in Patients at Metabolic Risk

Prevention and Treatment of Pediatric Obesity

Endocrine Society Clinical Guidelines Coming Soon:

- Endocrine Treatment of Transsexual Persons
- Managing Patients Post-Bariatric Surgery
- Vitamin D & Bone
- Continuous Glucose Monitoring
- Congenital Adrenal Hyperplasia
- Pituitary Incidentaloma
- Hypertriglyceridemia
- Hyperprolactinemia
- Intensive Insulin Therapy of Hospital Patients
- Management of Anabolic Drugs for Osteoporosis in Men



To purchase the available guidelines visit:

www.endo-society.org/guidelines/Current-Clinical-Practice-Guidelines.cfm.

To view patient guides (companion pieces to the clinical guidelines), visit

The Hormone Foundation's Web site at www.hormone.org/public/patientguides.cfm.



THE
ENDOCRINE
SOCIETY®

Commercial Reprint Information

For information on reprint requests of more than 101 and commercial reprints contact:

Reprint Sales Specialist
Cadmus Professional Communications

Fax: 410.684.2789
Email: reprints2@cadmus.com

Single Reprint Information

For information on reprints of 100 and fewer, complete the guideline order form and return using one of the following methods:

Mail: The Endocrine Society
c/o Bank of America
P.O. Box 630721
Baltimore, MD 21263-0721

Fax: 301.941.0257
Email: Societyservices@endo-society.org

Questions & Correspondences

The Endocrine Society
Attn: Government & Public Affairs Department
8401 Connecticut Avenue, Suite 900
Chevy Chase, MD 20815

Phone: 301.941.0200
Email: govt-prof@endo-society.org
Web: www.endo-society.org

For more information on The Endocrine Society's Clinical Practice Guidelines or to download the complete version of this guideline, visit <http://www.endo-society.org/guidelines/index.cfm>.





The Endocrine Society
8401 Connecticut Avenue, Suite 900
Chevy Chase, MD 20815

301.941.0200
www.endo-society.org